Document:

Exhibit 10.11

 

EMPLOYMENT AGREEMENT

 

This
Employment Agreement (the “Agreement”) is made and entered into as of April 10, 2018 (the “Effective
Date”), by and between Patrick Smith, an individual residing at 6830 Little Fox Trail, Cumming, GA 30040. (the “Executive”)
and The OLB Group, a Delaware corporation with its principal place of business at 200 Park Avenue, Suite 1700, New York, NY 10166
(the “Company”).

 

WHEREAS,
the Executive desires to be employed by the Company on such terms and conditions;

 

NOW,
THEREFORE, in consideration of the mutual covenants, promises, and obligations set forth herein, the parties agree as follows:

 

1.
Term/At-Will Employment. The Executive’s employment hereunder shall be effective as of the Effective Date and shall
continue until either party terminates the employment. Executive’s employment is at-will, meaning either party may terminate
the employment at any time for any reason or no reason without advance notice. This term of this Agreement may be altered only
by a writing signed by the Chief Executive Officer that specifically refers to this term of the Agreement. The period during which
the Executive is employed by the Company hereunder is hereinafter referred to as the “Employment Term.”

 

2.
Position and Duties.

 

2.1
Position. During the Employment Term, the Executive shall serve as the Vice President, Finance to Company’s Chief
Executive Officer. During the Employment Term, the Executive shall devote substantially all of his business time and attention
to the performance of the Executive’s duties hereunder and will not engage in any other business, profession, or occupation
for compensation or otherwise which would conflict or interfere with the performance of such services either directly or indirectly
without the prior written consent of the President.

 

2.2
Duties. In his position, the Executive shall have such duties, authority, and responsibility as are consistent with the
Executive’s position. These shall include direction and management of all Company financial activities and reporting including
the treasury function.

 

2.3
Place of Performance. The principal place of Executive’s employment shall be at 950 N. Point Parkway, Suite 400,
Alpharetta, GA 30005; provided that, the Executive may be required to travel on Company business during the Employment Term.

 

3.
Compensation.

 

3.1
Base Salary. The Company shall pay the Executive an annual base salary in the gross amount of $175,000 (One Hundred Seventy-Five
Thousand Dollars), less deductions applicable to wages in periodic installments in accordance with the Company’s customary
payroll practices and applicable wage payment laws, but no less frequently than monthly. The Executive’s annual base salary,
as in effect from time to time, is hereinafter referred to as “Base Salary.”

 

    

     

    

 

3.2
Bonus. Executive shall be eligible for an annual bonus of up to $45,000 (forty-five thousand dollars) less deductions applicable
to wages. The amount shall be determined by the Company in its reasonable discretion based upon performance metrics that shall
be determined in the Company’s reasonable discretion. The bonus shall be determined on a calendar year basis and pro-rated
for the first year of Executive’s employment base upon the number of week Executive is employed. Any bonus shall be paid
on or before January 15 of each new year. Executive must be employed on the date the bonus is paid in order to receive a bonus.

 

3.3
Restricted Stock Award. The Company shall, upon the Effective Date, grant Executive Seven Million Nine Hundred Fifty-Five
Thousand One Hundred Sixty-Eight (7,955,168) restricted options of common stock. The grant shall vest at the rate of one-fifth
(1/5th) beginning on each anniversary date of the Effective Date. No restricted stock will be granted after the termination
of Executive’s employment and any unvested restricted stock shall be forfeited upon the termination of Executive’s
employment. All terms of the restricted stock granted under this Agreement shall be governed by equity plan that the Company will
be adopting in the near future (the “Plan”). Insofar as the Plan and this Agreement conflict, the terms of
the Plan shall govern. To the extent permitted by applicable law and the Plan, in the event the Company makes a secondary offering
of stock in an amount exceeding $25,000,000 (Twenty-Five Million Dollars), the Company shall permit Executive to offer any of
his vested restricted shares for sale as part of any such secondary offering in the same amounts and proportions as other employees
of the Company.

 

3.4
Employee Benefits. During the Employment Term, the Executive shall be entitled to participate in all employee benefit plans,
practices, and programs maintained by the Company, as in effect from time to time (collectively, “Employee Benefit Plans”)
on a basis which is no less favorable than is provided to other similarly situated executives of the Company, to the extent consistent
with applicable law and the terms of the applicable Employee Benefit Plans. The Company reserves the right to amend or cancel
any Employee Benefit Plans at any time in its sole discretion, subject to the terms of such Employee Benefit Plans and applicable
law.

 

3.5
Vacation; Paid Time-Off. During the Employment Term, the Executive shall be entitled paid vacation in accordance with the
Company’s policies for executive officers as such policies may exist from time to time.

 

3.6
Business Expenses. The Executive shall be entitled to reimbursement for all reasonable and necessary out-of-pocket business,
entertainment, and travel expenses incurred by the Executive in connection with the performance of the Executive’s duties
hereunder in accordance with the Company’s expense reimbursement policies and procedures.

 

    2

     

    

 

4.
Termination of Employment.

 

4.1
Termination Notice and Date. The Employment Term and the Executive’s employment hereunder may be terminated by either
the Company or the Executive at any time and for any reason by giving written notice thereof. The date the employment terminates
shall be date notice of termination is communicated to a party (“Termination Date”).

 

4.2
Resignation of All Other Positions. Upon termination of the Executive’s employment hereunder for any reason, the
Executive, effective on the Termination Date, shall be deemed to have resigned automatically from all paid positions that the
Executive holds as an officer, employee, or member of the Board (or a committee thereof) of the Company, or as a paid officer,
employee, or board member of any of the Company’s affiliates.

 

5.
Cooperation. The parties agree that certain matters in which the Executive will be involved during the Employment Term
may necessitate the Executive’s cooperation in the future. Accordingly, following the termination of the Executive’s
employment for any reason, to the extent reasonably requested by the Board, the Executive shall cooperate with the Company in
connection with matters arising out of the Executive’s service to the Company; provided that, the Company shall make reasonable
efforts to minimize disruption of the Executive’s other activities. The Company shall reimburse the Executive for reasonable
expenses incurred in connection with such cooperation.

 

6.
Confidentiality.

 

6.1
At all times, Executive shall keep confidential, except as the Company may otherwise consent to in writing, and not disclose,
or make any use of except for the benefit of the Company, at any time either during or subsequent to performance by Executive
of services for the Company, any trade secrets, confidential information, knowledge, data or other information of the Company
relating to processes, know-how, technology, intellectual property, designs, technical data, business plans, strategies, or
other subject matter pertaining to any business of the Company or any of its partners, customers, consultants, licensors,
licensees or affiliates (collectively, the “Confidential Information”), which Executive may produce,
obtain or otherwise learn of during the course of Executive’s association with the Company, and whether produced,
obtained or learned of prior to, as of or following the date hereof. The “Confidential Information” shall not
include information that is or becomes part of the public domain not as a result of any inaction or action of Executive.
Executive shall not deliver, reproduce, or in any way allow any such Confidential Information to be delivered to or used by
any third parties for any purpose (including, without limitation, any purpose harmful to the interests of the Company)
without the specific direction or consent of a duly authorized representative of the Company.

 

    3

     

    

 

6.2
Notice of Immunity Under the Economic Espionage Act of 1996, as amended by the Defend Trade Secrets Act of 2016
(“DTSA”). Notwithstanding any other provision of this Agreement:

 

(a) The Executive will not be held
criminally or civilly liable under any federal or state trade secret law for any disclosure of a trade secret that:

 

(1) is
made (A) in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney; and
(B) solely for the purpose of reporting or investigating a suspected violation of law; or

 

(2) is
made in a complaint or other document filed under seal in a lawsuit or other proceeding.

 

(b)
If the Executive files a lawsuit for retaliation by the Company for reporting a suspected violation of law, the Executive may
disclose the Company’s trade secrets to the Executive’s attorney and use the trade secret information in the court
proceeding if the Executive:

 

(1) files
any document containing trade secrets under seal; and

 

(2) does
not disclosure trade secrets except pursuant to court order.

 

7.3
Nothing herein shall prevent Executive from making a report, or bringing a claim, to any governmental agency, including the
U.S. Equal Employment Opportunity Commission, the National Labor Relations Board, the U.S. Department of Justice, or the
Attorney General of the State of New York.

 

7.
Work Made for Hire; Assignment. The Executive acknowledges that, by reason of being employed by the Company at the relevant
times, to the extent permitted by law, all of the Work Product consisting of copyrightable subject matter is “work made
for hire” as defined in 17 U.S.C. § 101 and such copyrights are therefore owned by the Company. To the extent that
the foregoing does not apply, the Executive hereby irrevocably assigns to the Company, for no additional consideration, the Executive’s
entire right, title, and interest in and to all Work Product and Intellectual Property Rights therein, including the right to
sue, counterclaim, and recover for all past, present, and future infringement, misappropriation, or dilution thereof, and all
rights corresponding thereto throughout the world. Nothing contained in this Agreement shall be construed to reduce or limit the
Company’s rights, title, or interest in any Work Product or Intellectual Property Rights so as to be less in any respect
than that the Company would have had in the absence of this Agreement.

 

8.
Restrictive Covenants. Executive acknowledges and recognizes the highly competitive nature of the businesses of the Company
and its subsidiaries and affiliates and accordingly agrees as follows:

 

(a)
During Executive’s employment with the Company and for a period of one (1) year from the date of termination of
Executive’s employment for any reason (the “Restriction Period”), Executive shall not, within a
twenty-five mile radius of the Company’s Atlanta, Georgia office, either as principal, agent, employee, consultant,
partner, officer, director, shareholder, or in any other individual or representative capacity, own, manage, finance,
operate, control or otherwise engage or participate in any manner or fashion in a business competitive with the
Company.

 

    4

     

    

 

(b)
Executive further agrees, for the benefit of the Company and its affiliates, that during the Restriction Period, Executive shall
not, directly or indirectly, either as principal, agent, employee, consultant, partner, officer, director, shareholder, or in
any other individual or representative capacity, on your behalf or any other person or entity other than the Company or its affiliates
(i) solicit or induce, or attempt to solicit or induce, directly or indirectly, any customer or prospective customer of the Company
with whom the Executive has had personal contact within the six-month period prior to the Termination Date; or (ii) solicit or
induce, or attempt to solicit or induce, directly or indirectly any person who is, or during the six months prior to the termination
of your employment with the Company was, an employee or agent of, or consultant to, the Company or any of its affiliates to terminate
its, his or her relationship therewith, or (iii) hire or engage any person who is, or during the six months prior to the termination
of your employment with the Company was, an employee, agent of or consultant to the Company or any of its affiliates.

 

(c) Executive
understands that the provisions of this Section may limit Executive’s ability to earn a livelihood in a business similar
to the business of the Company but Executive nevertheless agrees and hereby acknowledges that (i) such provisions do not impose
a greater restraint than is necessary to protect the goodwill or other business interests of the Company, (ii) such provisions
contain reasonable limitations as to time and scope of activity to be restrained, (iii) such provisions are not harmful to the
general public, (iv) such provisions are not unduly burdensome to you, and (v) the consideration provided hereunder is sufficient
to compensate you for the restrictions contained in this Section. In consideration of the foregoing and in light of Executive’s
education, skills and abilities, you agree that you shall not assert that, and it should not be considered that, any provisions
of Section otherwise are void, voidable or unenforceable or should be voided or held unenforceable.

 

(d) If
a judicial determination is made by a court of competent jurisdiction that the time or territory or any other restriction contained
in this Agreement is an unenforceable restriction against you, the provisions of this Agreement shall not be rendered void but
shall be deemed amended to apply as to such maximum time and territory and to such maximum extent as such court may judicially
determine or indicate to be enforceable. Alternatively, if any court of competent jurisdiction finds that any restriction contained
in this Agreement is unenforceable, and such restriction cannot be amended so as to make it enforceable, such finding shall not
affect the enforceability of any of the other restrictions contained herein.

 

(e) In
the event that Executive violates any of the restrictive covenants set forth in Section, in addition to any other remedy which
may be available (i) at law or in equity, (ii) pursuant to any other provision of this Agreement or (iii) pursuant to any applicable
equity award agreement, all outstanding stock options to purchase shares of Company common stock and other unvested equity awards
granted to Executive shall be automatically forfeited effective as of the date on which such violation first occurs.

 

9.
Remedies. In the event of a breach or threatened breach by the Executive of Sections “7”, “8”,
or “9” of this Agreement, the Executive hereby consents and agrees that the Company shall be entitled to seek, in
addition to other available remedies, a temporary or permanent injunction or other equitable relief against such breach or threatened
breach from any court of competent jurisdiction, without the necessity of showing any actual damages or that money damages would
not afford an adequate remedy, and without the necessity of posting any bond or other security. The aforementioned equitable relief
shall be in addition to, not in lieu of, legal remedies, monetary damages, or other available forms of relief.

 

    5

     

    

 

10.
Arbitration.

 

10.1
JURY TRIAL WAIVER. THE PARTIES EXPRESSLY AND KNOWINGLY WAIVE ANY RIGHT TO A JURY TRIAL IN THE EVENT ANY ACTION ARISING
UNDER OR IN CONNECTION WITH THIS AGREEMENT OR YOUR EMPLOYMENT WITH THE COMPANY IS LITIGATED OR HEARD IN ANY COURT.

 

10.2
Dispute Resolution/Arbitration. The parties agree that all claims, disputes, and/or controversies arising under this Agreement
and/or related to the your employment hereunder or the termination of such employment (whether or not based on contract, tort
or upon any federal, state or local statute, including but not limited to claims asserted under the Age Discrimination in Employment
Act, as amended, Title VII of the Civil Rights Act of 1964, as amended, any state Fair Employment Practices Act, and/or the Americans
with Disabilities Act), shall be resolved exclusively through mediation/arbitration by JAMS, in the County of New York in the
State of New York, in accordance with the JAMS Rules and Procedures for Mediation/Arbitration of Employment Disputes; provided,
however, that in the event that the Company alleges that Executive is in breach of any of the provisions contained in Sections
7 or 8, the Company shall not be exclusively required to submit such dispute to mediation/arbitration. In such event, the Company
may, at its option, seek and obtain from any court having jurisdiction, injunctive or equitable relief, in addition to pursuing
at arbitration all other remedies available to it (including without limitation any claims for relief arising out of any breach
of Sections 7 or 8 of this Agreement).

 

11.
Exit Obligations. Upon (a) voluntary or involuntary termination of the Executive’s employment or (b) the Company’s
request at any time during the Executive’s employment, the Executive shall (i) provide or return to the Company any and
all Company property, including keys, key cards, access cards, identification cards, security devices, employer credit cards,
network access devices, computers, cell phones, smartphones, PDAs, pagers, fax machines, equipment, speakers, webcams, manuals,
reports, files, books, compilations, work product, email messages, recordings, tapes, disks, thumb drives or other removable information
storage devices, hard drives, negatives and data and all Company documents and materials belonging to the Company and stored in
any fashion, including but not limited to those that constitute or contain any Confidential Information or Work Product, that
are in the possession or control of the Executive, whether they were provided to the Executive by the Company or any of its business
associates or created by the Executive in connection with his employment by the Company; and (ii) delete or destroy all copies
of any such documents and materials not returned to the Company that remain in the Executive’s possession or control, including
those stored on any non-Company devices, networks, storage locations, and media in the Executive’s possession or control.

 

    6

     

    

 

12.
Publicity. The Executive hereby irrevocably consents to any and all uses and displays, by the Company and its agents, representatives
and licensees, of the Executive’s name, voice, likeness, image, appearance, and biographical information.

 

13.
Governing Law: Jurisdiction and Venue. This Agreement, for all purposes, shall be construed in accordance with the laws
of New York without regard to conflicts of law principles, except for the arbitration provision which shall be governed solely
by the Federal Arbitration Act. Any action or proceeding by either of the parties to enforce this Agreement shall be brought only
in a state or federal court located in the State of New York, having jurisdiction over the County of New York. The parties hereby
irrevocably submit to the non-exclusive jurisdiction of such courts and waive the defense of inconvenient forum to the maintenance
of any such action or proceeding in such venue.

 

14.
Entire Agreement. Unless specifically provided herein, this Agreement contains all of the understandings and representations
between the Executive and the Company pertaining to the subject matter hereof and supersedes all prior and contemporaneous understandings,
agreements, representations and warranties, both written and oral, with respect to such subject matter. The parties warrant that,
in agreeing to the terms of this Agreement, they have not relied upon any oral statements or upon any written statements not contained
in this Agreement. The parties mutually agree that the Agreement can be specifically enforced in court and can be cited as evidence
in legal proceedings alleging breach of the Agreement.

 

15.
Modification and Waiver. No provision of this Agreement may be amended or modified unless such amendment or modification
is agreed to in writing and signed by the Executive and by the President of the Company. No waiver by either of the parties of
any breach by the other party hereto of any condition or provision of this Agreement to be performed by the other party hereto
shall be deemed a waiver of any similar or dissimilar provision or condition at the same or any prior or subsequent time, nor
shall the failure of or delay by either of the parties in exercising any right, power, or privilege hereunder operate as a waiver
thereof to preclude any other or further exercise thereof or the exercise of any other such right, power, or privilege.

 

16.
Severability. Should any provision of this Agreement be held by a court of competent jurisdiction to be enforceable only
if modified, or if any portion of this Agreement shall be held as unenforceable and thus stricken, such holding shall not affect
the validity of the remainder of this Agreement, the balance of which shall continue to be binding upon the parties with any such
modification to become a part hereof and treated as though originally set forth in this Agreement.

 

16.1
The parties further agree that any such court is expressly authorized to modify any such unenforceable provision of this Agreement
in lieu of severing such unenforceable provision from this Agreement in its entirety, whether by rewriting the offending provision,
deleting any or all of the offending provision, adding additional language to this Agreement, or by making such other modifications
as it deems warranted to carry out the intent and agreement of the parties as embodied herein to the maximum extent permitted
by law.

 

16.2
The parties expressly agree that this Agreement as so modified by the court shall be binding upon and enforceable against
each of them. In any event, should one or more of the provisions of this Agreement be held to be invalid, illegal, or
unenforceable in any respect, such invalidity, illegality, or unenforceability shall not affect any other provisions hereof,
and if such provision or provisions are not modified as provided above, this Agreement shall be construed as if such invalid,
illegal, or unenforceable provisions had not been set forth herein.

 

    7

     

    

 

17.
Captions. Captions and headings of the sections and paragraphs of this Agreement are intended solely for convenience and
no provision of this Agreement is to be construed by reference to the caption or heading of any section or paragraph.

 

18.
Counterparts. This Agreement may be executed in separate counterparts, each of which shall be deemed an original, but all
of which taken together shall constitute one and the same instrument. Facsimile and .pdf signatures of this Agreement shall be
considered originals for purposes of this Agreement.

 

19.
Tolling. Should the Executive violate any of the terms of the restrictive covenant obligations articulated herein, the
obligation at issue will run from the first date on which the Executive ceases to be in violation of such obligation.

 

20.
Successors and Assigns. This Agreement is personal to the Executive and shall not be assigned by the Executive. Any purported
assignment by the Executive shall be null and void from the initial date of the purported assignment. The Company may assign thiShould the Executive violate any of the terms of the restrictive covenant obligations articulated herein, the
obligation at issue will run from the first date on which the Executive ceases to be in violation of such obligation.s
Agreement to any successor or assign (whether direct or indirect, by purchase, merger, consolidation, or otherwise) to all or
substantially all of the business or assets of the Company. This Agreement shall inure to the benefit of the Company and permitted
successors and assigns.

 

21.
Notice. Notices and all other communications provided for in this Agreement shall be in writing and shall be delivered
personally or sent by registered or certified mail, return receipt requested, or by overnight carrier to the parties at the addresses
set forth below (or such other addresses as specified by the parties by like notice):

 

If
to the Company:

 

The
OLB Group

200
Park Avenue, Suite1700

New York, NY, 10166

Attn:
Ronny Yakov, CEO

 

with
a copy to (which will not constitute notice) to:

 

Ellenoff,
Grossman & Schole, LLP

1345
Avenue of the Americas, 11th Floor

New
York, NY 10105

Attn:
Matthew Bernstein, Esq.

Email:
mbernstein@egsllp.com

Telephone:
(212) 370-1300

Facsimile:
(212) 370-7889

 

    8

     

    

 

If
to the Executive:

 

Patrick
Smith

6830
Little Fox Trail,

Cumming, GA 30040

 

22.
Representations of the Executive. The Executive represents and warrants to the Company that:

 

22.1
The Executive’s acceptance of employment with the Company and the performance of his duties hereunder will not conflict
with or result in a violation of, a breach of, or a default under any contract, agreement, or understanding to which he is a party
or is otherwise bound; and

 

22.2
The Executive’s acceptance of employment with the Company and the performance of his duties hereunder will not violate any
non-solicitation, non-competition, or other similar covenant or agreement of a prior employer.

 

23.
Withholding. The Company shall have the right to withhold from any amount payable hereunder any Federal, state, and local
taxes in order for the Company to satisfy any withholding tax obligation it may have under any applicable law or regulation.

 

24.
Survival. Upon the expiration or other termination of this Agreement, the respective rights and obligations of the parties
hereto shall survive such expiration or other termination to the extent necessary to carry out the intentions of the parties under
this Agreement.

 

25.
Acknowledgement of Full Understanding. THE EXECUTIVE ACKNOWLEDGES AND AGREES THAT HE HAS FULLY READ, UNDERSTANDS AND VOLUNTARILY
ENTERS INTO THIS AGREEMENT. THE EXECUTIVE ACKNOWLEDGES AND AGREES THAT HE HAS HAD AN OPPORTUNITY TO ASK QUESTIONS AND CONSULT
WITH AN ATTORNEY OF HIS CHOICE BEFORE SIGNING THIS AGREEMENT.

 

[Signature
page follows]

 

    9

     

    

 

IN
WITNESS WHEREOF, the parties hereto have executed this Employment Agreement as of the date first above written.

 

		 	The OLB Group, Inc.
	 	 	 	 
		 	By:	/s/
    Ronny Yakov
		 	Name:	Ronny Yakov
		 	Title:	Chief Executive Officer
	 	 	 	 
	AGREED TO AND ACCEPTED:	 	 	 
	 	 	 	 
	/s/
    Patrick Smith	 	 	 
	Patrick Smith	 	 	 

 

 

10Exhibit 4.2

    

    
      	
               

            

    

  

  

    CASTLE BIOSCIENCES, INC.

     

    FIFTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT

     

    July 15, 2015

    

    

    
      	
               

            

    

     

    
      
        
 

    

    
    

      TABLE OF CONTENTS

       

      	 	 	 	
              Page

            
	 	 	 	 
	
              SECTION 1. 

            	
              DEFINITIONS

            	
              1

            
	 	 	 	 
	
              1.1

            	 	
              Certain Definitions

            	
              1

            
	 	 	 	 
	
              SECTION 2. 

            	
              REGISTRATION RIGHTS

            	
              5

            
	 	 	 	 
	
              2.1

            	 	
              Requested Registration

            	
              5

            
	
              2.2

            	 	
              Company Registration

            	
              7

            
	
              2.3

            	 	
              Registration on Form S-3

            	
              8

            
	
              2.4

            	 	
              Expenses of Registration

            	
              9

            
	
              2.5

            	 	
              Registration Procedures

            	
              9

            
	
              2.6

            	 	
              Indemnification

            	
              11

            
	
              2.7

            	 	
              Information by Holder

            	
              12

            
	
              2.8

            	 	
              Restrictions on Transfer

            	
              13

            
	
              2.9

            	 	
              Rule 144 Reporting

            	
              14

            
	
              2.10

            	 	
              Market Stand-Off Agreement

            	
              14

            
	
              2.11

            	 	
              Delay of Registration

            	
              15

            
	
              2.12

            	 	
              Transfer or Assignment of Registration Rights

            	
              15

            
	
              2.13

            	 	
              Limitations on Subsequent Registration Rights

            	
              15

            
	
              2.14

            	 	
              Termination of Registration Rights

            	
              15

            
	 	 	 	 
	
              SECTION 3.

            	
              INFORMATION COVENANTS OF THE COMPANY

            	
              15

            
	 	 	 	 
	
              3.1

            	 	
              Basic Financial Information and Inspection Rights

            	
              15

            
	
              3.2

            	 	
              Confidentiality

            	
              16

            
	
              3.3

            	 	
              Termination of Covenants

            	
              17

            
	 	 	 	 
	
              SECTION 4.

            	
              RIGHT OF FIRST REFUSAL

            	
              17

            
	 	 	 	 
	
              4.1

            	 	
              Right of First Refusal to Significant Holders

            	
              17

            
	
              4.2

            	 	
              Termination of Covenants

            	
              18

            
	 	 	 	 
	
              SECTION 5.

            	
              BOARD OF DIRECTORS AND STOCKHOLDERS MATTERS

            	
              19

            
	 	 	 	 
	
              5.1

            	 	
              Board Meetings

            	
              19

            
	
              5.2

            	 	
              Directors and Officers Insurance

            	
              19

            
	
              5.3

            	 	
              Matters Requiring Board Approval

            	
              19

            
	
              5.4

            	 	
              Matters Requiring Approval by the Major Investors

            	
              20

            
	
              5.5

            	 	
              FCPA

            	
              21

            
	
              5.6

            	 	
              Termination of Covenants

            	
              22

            
	 	 	 	 
	
              SECTION 6.

            	
              EMPLOYEE MATTERS

            	
              22

            
	 	 	 	 
	
              6.1

            	 	
              Employee Proprietary Information Agreements

            	
              22

            
	
              6.2

            	 	
              Key Person Insurance

            	
              22

            
	
              6.3

            	 	
              Employee Stock

            	
              22

            
	
              6.4

            	 	
              Termination of Covenants

            	
              22

            
	 	 	 	 
	
              SECTION 7.

            	
              MISCELLANEOUS

            	
              22

            
	 	 	 	 
	
              7.1

            	 	
              Amendment

            	
              22

            
	
              7.2

            	 	
              Notices

            	
              23

            
	
              7.3

            	 	
              Governing Law

            	
              23

            
	
              7.4

            	 	
              Successors and Assigns

            	
              23

            
	
              7.5

            	 	
              Entire Agreement

            	
              23

            

      

      

      
        -i-

        
          
 

      

      TABLE OF CONTENTS

      (continued)

      

      

      

      

      	 	 	 	
              Page

            
	 	 	 	 
	
              7.6

            	 	
              Delays or Omissions

            	
              24

            
	
              7.7

            	 	
              Severability

            	
              24

            
	
              7.8

            	 	
              Titles and Subtitles

            	
              24

            
	
              7.9

            	 	
              Counterparts

            	
              24

            
	
              7.10

            	 	
              Telecopy Execution and Delivery

            	
              24

            
	
              7.11

            	 	
              Further Assurances

            	
              24

            
	
              7.12

            	 	
              Aggregation of Stock

            	
              25

            

      

      

      
        -ii-

        
          
 

      

      

    

    CASTLE BIOSCIENCES, INC.

     

    FIFTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT

     

    This Fifth Amended and Restated Investors’ Rights Agreement (this “Agreement”) is dated as of July 15, 2015, and is between Castle Biosciences, Inc., a Delaware corporation (the “Company”), and the persons and entities listed on Exhibit A hereto (each, an “Investor” and collectively, the “Investors”). This Agreement amends and restates that
      certain Fourth Amended and Restated Investors’ Rights Agreement dated August 11, 2014 (the “Prior Agreement”), by and
      between the Company and certain of the Investors. Unless otherwise defined herein, capitalized terms used in this Agreement have the meanings ascribed to them in Section 1.

     

    RECITALS

     

    WHEREAS, certain of the
      Investors hold shares of the Company’s Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, and/or Series E Preferred Stock and possess registration rights, information rights, rights of first offer
      and other rights pursuant to the Prior Agreement;

     

    WHEREAS, pursuant to Section
      7.1 of the Prior Agreement, any term of the Prior Agreement may be amended or waived with the written consent of the Company and the Holders (as defined in the Prior Agreement) holding at least a majority of the Registrable Securities (as defined in
      the Prior Agreement) and each of the Major Investors (as defined in the Prior Agreement) (the “Required Approval”);

     

    WHEREAS, the undersigned,
      constituting the Required Approval, desire to amend and restate the Prior Agreement, waive certain rights thereunder and accept the rights created pursuant to this Agreement in lieu of the rights granted to them under the Prior Agreement; and

     

    WHEREAS, the Company and
      certain of the Investors are parties to the Series F Preferred Stock Purchase Agreement of even date herewith (the “Purchase
        Agreement”), and it is a condition to the closing of the transactions contemplated by the Purchase Agreement that the Company and such Investors execute and deliver this Agreement.

     

    AGREEMENT

     

    NOW, THEREFORE: In
      consideration of the mutual promises and covenants set forth herein, and other consideration, the receipt and adequacy of which is hereby acknowledged, the parties hereto agree as follows:

     

    SECTION 1.

      

      DEFINITIONS

     

    1.1          Certain Definitions. As used in this Agreement, the following terms shall have the
        meanings set forth below:

     

    (a)          “Certificate of Incorporation” shall mean the Company’s Seventh Amended and Restated Certificate of Incorporation, as may
        be amended from time to time.

     

  

  
    1

    
      
 

  

  

     

    (b)          “Commission” shall mean the Securities and Exchange Commission or any other federal agency at the time administering the
        Securities Act.

     

    (c)          “Common Stock” means the Common Stock of the Company.

     

    (d)          “Conversion Stock” shall mean shares of Common Stock issued upon conversion of the Preferred Stock.

     

    (e)          “Exchange Act” shall mean the Securities Exchange Act of 1934, as amended, or any similar successor federal statute and the
        rules and regulations thereunder, all as the same shall be in effect from time to time.

     

    (f)          “Holder” shall mean any Investor who holds Registrable Securities and any holder of Registrable Securities to whom the
        registration rights conferred by this Agreement have been duly and validly transferred in accordance with Section 2.12 of this Agreement.

     

    (g)          “Indemnified Party” shall have the meaning set forth in Section 2.6(c).

     

    (h)          “Indemnifying Party” shall have the meaning set forth in Section 2.6(c).

     

    (i)          “Initial Public Offering” shall mean the closing of the Company’s first firm commitment underwritten public offering of the
        Company’s Common Stock registered under the Securities Act.

     

    (j)          “Initiating Holders” shall mean any Holder or Holders who in the aggregate hold not less than fifty percent (50%) of the
        outstanding Registrable Securities and, prior to a Threshold Event, each of the Major Investors.

     

    (k)          “Liquidation Event” shall mean a Liquidation Event as defined in the Certificate of Incorporation or a Deemed Liquidation
        Event as defined in the Certificate of Incorporation.

     

    (l)          “Major Investor” shall mean any of BioBrit, LLC, Industry Ventures Healthcare, LLC, MGC Venture Partners 2013, L.P. and
        Sofinnova HealthQuest Partners, L.P. in each case for so long as such Major Investor (or its affiliated entities (including affiliated venture capital funds)) holds at least 50,000 aggregate shares of Series F Preferred Stock, Series E-2 Preferred
        Stock, Series E-3 Preferred Stock and/or Series E-2A Preferred Stock (as appropriately adjusted for any stock split, dividend, combination or other recapitalization).

     

    (m)          “New Securities” shall have the meaning set forth in Section 4.1(a).

     

    (n)          “Other Selling Stockholders” shall mean persons other than Holders who, by virtue of agreements with the Company approved
        by the board of directors of the Company (including each of the Preferred Directors), are entitled to include their Other Shares in certain registrations hereunder.

     

    (o)          “Other Shares” shall mean shares of Common Stock, other than Registrable Securities (as defined below), with respect to
        which registration rights have been granted and approved by the board of directors of the Company (including each of the Preferred Directors).

     

    (p)          “Preferred Director” shall have the meaning set forth in the Certificate of Incorporation.

     

    
      2

      
        
 

    

     

    (q)          “Preferred Stock” shall mean the Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D
        Preferred Stock, Series E-1 Preferred Stock, Series E-2 Preferred Stock, Series E-3 Preferred Stock, Series E-2A Preferred Stock and Series F Preferred Stock.

     

    (r)          “Registrable Securities” shall mean (i) shares of Common Stock issued or issuable pursuant to the conversion of the Shares
        and (ii) any Common Stock issued as a dividend or other distribution with respect to or in exchange for or in replacement of the shares referenced in (i) above; provided, however, that Registrable Securities shall not include any shares of Common Stock described in clause (i) or (ii) above which have previously been registered or which have been sold to the public either
        pursuant to a registration statement or Rule 144, or which have been sold in a private transaction in which the transferor’s rights under this Agreement are not validly assigned in accordance with this Agreement.

     

    (s)          The terms “register,” “registered” and “registration” shall refer to a registration effected by preparing and
        filing a registration statement in compliance with the Securities Act and applicable rules and regulations thereunder, and the declaration or ordering of the effectiveness of such registration statement.

     

    (t)          “Registration Expenses” shall mean all expenses incurred in effecting any registration pursuant to this Agreement,
        including, without limitation, all registration, qualification, and filing fees, printing expenses, escrow fees, fees and disbursements of counsel for the Company, blue sky fees and expenses, and expenses of any regular or special audits incident
        to or required by any such registration, but shall not include Selling Expenses, fees and disbursements of counsel for the Holders and the compensation of regular employees of the Company, which shall be paid in any event by the Company.

     

    (u)          “Reporting Date” shall mean the date upon which the Company first becomes subject to the periodic reporting requirements of
        Section 12(g) or Section 15(d) of the Exchange Act.

     

    (v)          “Restricted Securities” shall mean any Registrable Securities required to bear the first legend set forth in Section
        2.8(b).

     

    (w)          “Rule 144” shall mean Rule 144 as promulgated by the Commission under the Securities Act, as such Rule may be amended from
        time to time, or any similar successor rule that may be promulgated by the Commission.

     

    (x)          “Rule 145” shall mean Rule 145 as promulgated by the Commission under the Securities Act, as such Rule may be amended from
        time to time, or any similar successor rule that may be promulgated by the Commission

     

    (y)          “Securities Act” shall mean the Securities Act of 1933, as amended, or any similar successor federal statute and the rules
        and regulations thereunder, all as the same shall be in effect from time to time.

     

    (z)          “Selling Expenses” shall mean all underwriting discounts, selling commissions and stock transfer taxes applicable to the
        sale of Registrable Securities and fees and disbursements of counsel for any Holder (other than the fees and disbursements of one special counsel to the Holders included in Registration Expenses).

     

    (aa)          “Series A Preferred Stock” shall mean the shares of Series A Preferred Stock of the Company.

     

    
      3

      
        
 

    

     

    (bb)          “Series B Preferred Stock” shall mean the shares of Series B Preferred Stock of the Company.

     

    (cc)          “Series C Preferred Stock” shall mean the shares of Series C Preferred Stock of the Company.

     

    (dd)          “Series D Preferred Stock” shall mean the shares of Series D Preferred Stock of the Company.

     

    (ee)          “Series E Preferred Stock” shall mean the shares of Series E-1 Preferred Stock, the shares of Series E-2 Preferred Stock,
        the shares of Series E-3 Preferred Stock and the shares of Series E-2A Preferred Stock, together as a single class and not as separate series.

     

    (ff)          “Series E-1 Preferred Stock” shall mean the shares of Series E-1 Preferred Stock of the Company.

     

    (gg)          “Series E-2 Preferred Stock” shall mean the shares of Series E-2 Preferred Stock of the Company.

     

    (hh)          “Series E-3 Preferred Stock” shall mean the shares of Series E-3 Preferred Stock of the Company.

     

    (ii)          “Series E-2A Preferred Stock” shall mean the shares of Series E-2A Preferred Stock of the Company.

     

    (jj)          “Series F Preferred Stock” shall mean the shares of Series F Preferred Stock of the Company.

     

    (kk)        “Shares” shall mean shares of Series A Preferred Stock, shares of Series B Preferred Stock, shares of Series C Preferred
        Stock, shares of Series D Preferred Stock, shares of Series E-1 Preferred Stock, shares of Series E-2 Preferred Stock, shares of Series E-3 Preferred Stock, shares of Series E-2A Preferred Stock and shares of Series F Preferred Stock.

     

    (ll)          “Significant Holders” shall have the meaning set forth in Section 4.1.

     

    (mm)          “Threshold Event” shall mean a Liquidation Event or Deemed Liquidation Event (each as defined in the Certificate of
        Incorporation) pursuant to which (i) the holders of Series E-1 Preferred Stock would receive at the initial closing of such Liquidation Event or Deemed Liquidation Event consideration having a value equal to at least three (3) times the Original
        Issue Price (as defined in the Certificate of Incorporation) of the Series E-1 Preferred Stock, (ii) the holders of Series E-2 Preferred Stock would receive at the initial closing of such Liquidation Event or Deemed Liquidation Event consideration
        having a value equal to at least three (3) times the Original Issue Price of the Series E-2 Preferred Stock, (iii) the holders of Series E-3 Preferred Stock would receive at the initial closing of such Liquidation Event or Deemed Liquidation Event
        consideration having a value equal to at least three (3) times the Original Issue Price of the Series E-3 Preferred Stock, (iv) the holders of Series E-2A Preferred Stock would receive at the initial closing of the Liquidation Event or Deemed
        Liquidation Event consideration having a value equal to at least three (3) times the Original Issue Price of the Series E-2A Preferred Stock, and (v) the holders of Series F Preferred Stock would receive at the initial closing of the Liquidation
        Event or Deemed Liquidation Event consideration having a value equal to at least three (3) times the Original Issue Price of the Series F Preferred Stock.

    
      4

      
        
 

    

    SECTION 2.

    

      REGISTRATION RIGHTS

     

    2.1          Requested Registration.

     

    (a)          Request for Registration. Subject to the conditions set forth in this Section 2.1, if the Company shall receive from
        Initiating Holders a written request signed by such Initiating Holders that the Company effect any registration with respect to all or a part of the Registrable Securities (such request shall state the number of shares of Registrable Securities to
        be disposed of by such Initiating Holders and whether the offering will be underwritten and/or on a Form S-1), the Company will:

     

    (i)        promptly give
        written notice of the proposed registration to all other Holders; and

     

    (ii)       as soon as
        practicable, file and use its commercially reasonable efforts to effect such registration (including, without limitation, filing post-effective amendments, appropriate qualifications under applicable blue sky or other state securities laws, and
        appropriate compliance with the Securities Act) and to permit or facilitate the sale and distribution of all or such portion of such Registrable Securities as are specified in such request, together with all or such portion of the Registrable
        Securities of any Holder or Holders joining in such request as are specified in a written request received by the Company within twenty (20) days after such written notice from the Company is mailed or delivered.

     

    (b)          Limitations on Requested Registration. The Company shall not be obligated to effect, or to take any action to effect, any
        such registration pursuant to this Section 2.1:

     

    (i)         Prior to the
        earlier of (A) the five (5) year anniversary of the date of this Agreement or (B) one hundred eighty (180) days following the effective date of the first registration statement filed by the Company covering an underwritten offering of any of its
        securities to the general public;

     

    (ii)        If the
        Initiating Holders, together with the holders of any other securities of the Company entitled to inclusion in such registration statement, propose to sell Registrable Securities and such other securities (if any) the aggregate proceeds of which
        (after deduction for underwriter’s discounts and expenses related to the issuance) are less than $10,000,000;

     

    (iii)       In any
        particular jurisdiction in which the Company would be required to execute a general consent to service of process in effecting such registration, qualification, or compliance, unless the Company is already subject to service in such jurisdiction
        and except as may be required by the Securities Act;

     

    (iv)       After the
        Company has completed two such registrations pursuant to this Section 2.1;

     

    (v)        During the
        period starting with the date ninety (90) days prior to the Company’s good faith estimate of the date of filing of, and ending on a date ninety (90) days after the effective date of, a Company-initiated registration (or ending on the subsequent
        date on which all market stand-off agreements applicable to the offering have terminated); provided that the Company is actively
        employing in good faith commercially reasonable efforts to cause such registration statement to become effective;

    
      5

      
        
 

    

    (vi)       If the
        Initiating Holders propose to dispose of shares of Registrable Securities that may be registered on Form S-3 in an underwritten offering pursuant to a request made under Section 2.3 (i n which case Section 2.3 shall apply to such registration
        demand);

     

    (vii)       If the
        Initiating Holders do not request that such offering be firmly underwritten by underwriters selected by the Initiating Holders (subject to the reasonable consent of the Company); or

     

    (viii)      If the
        Company and the Initiating Holders are unable to obtain the commitment of an underwriter as described in clause (b)(vii) above to firmly underwrite the offer.

     

    (c)          Deferral. If (i) in the good faith judgment of the board of directors of the Company, the filing of a registration
        statement covering the Registrable Securities would be materially detrimental to the Company and the board of directors of the Company concludes, as a result, that it is in the best interests of the Company to defer the filing of such registration
        statement at such time, and (ii) the Company shall furnish to such Holders a certificate signed by the President of the Company stating that in the good faith judgment of the board of directors of the Company, it would be materially detrimental to
        the Company for such registration statement to be filed in the near future and that it is, therefore, in the best interests of the Company to defer the filing of such registration statement, then (in addition to the limitations set forth in Section
        2.1(b)(v) above) the Company shall have the right to defer such filing for a period of not more than one hundred twenty (120) days after receipt of the request of the Initiating Holders, and, provided further, that

        the Company shall not defer its obligation in this manner more than once in any twelve-month period.

     

    (d)          Other Shares. The registration statement filed pursuant to the request of the Initiating Holders may, subject to the
        provisions of Section 2.1(e), include Other Shares, and may include securities of the Company being sold for the account of the Company.

     

    (e)          Underwriting. The right of any Holder to include all or any portion of its Registrable Securities in a registration
        pursuant to this Section 2.1 shall be conditioned upon such Holder’s participation in an underwriting and the inclusion of such Holder’s Registrable Securities to the extent provided herein. If the Company shall request inclusion in any
        registration pursuant to Section 2.1 of securities being sold for its own account, or if other persons shall request inclusion in any registration pursuant to Section 2.1, the Initiating Holders shall, on behalf of all Holders, offer to include
        such securities in the underwriting and such offer shall be conditioned upon the participation of the Company or such other persons in such underwriting and the inclusion of the Company’s and such person’s other securities of the Company and their
        acceptance of the further applicable provisions of this 2 (including Section 2.10). The Company shall (together with all Holders and other persons proposing to distribute their securities through such underwriting) enter into an underwriting
        agreement in customary form with the representative of the underwriter or underwriters selected for such underwriting by the Initiating Holders holding a majority of the Registrable Securities held by all Initiating Holders, which underwriters are
        reasonably acceptable to the Company.

     

    Notwithstanding any other provision of this Section 2.1, if the underwriters advise the Initiating Holders in writing that marketing
      factors require a limitation on the number of shares to be underwritten, the number of Registrable Securities and Other Shares that may be so included shall be allocated as follows: (i) first, among all Holders requesting to include Registrable
      Securities in such registration statement based on the pro rata percentage of Registrable Securities held by such Holders, assuming
      conversion; (ii) second, to the Other Selling Stockholders; and (iii) third, to the Company, which the Company may allocate, at its discretion, for its own account, or for the account of other holders or employees of the Company.

     

    If a person who has requested inclusion in such registration as provided above does not agree to the terms of any such underwriting, such
      person shall be excluded therefrom by written notice from the Company, the underwriter or the Initiating Holders. The securities so excluded shall also be withdrawn from registration. Any Registrable Securities or other securities excluded or
      withdrawn from such underwriting shall also be withdrawn from such registration. If shares are so withdrawn from the registration and if the number of shares to be included in such registration was previously reduced as a result of marketing factors
      pursuant to this Section 2.1(e), then the Company shall then offer to all Holders and Other Selling Stockholders who have retained rights to include securities in the registration the right to include additional Registrable Securities or Other Shares
      in the registration in an aggregate amount equal to the number of shares so withdrawn, with such shares to be allocated among such Holders and other Selling Stockholders requesting additional inclusion, as set forth above.

    
      6

      
        
 

    

     

    2.2          Company Registration.

     

    (a)          Company Registration. If the Company shall determine to register any of its securities either for its own account or the
        account of a security holder or holders, other than a registration pursuant to Section 2.1 or 2.3, a registration relating solely to employee benefit plans, a registration relating to the offer and sale of debt securities, a registration relating
        to a corporate reorganization or other Rule 145 transaction, or a registration on any registration form that does not permit secondary sales, the Company will:

     

    (i)          promptly
        give written notice of the proposed registration to all Holders; and

     

    (ii)        use its
        commercially reasonable efforts to include in such registration (and any related qualification under blue sky laws or other compliance), except as set forth in Section 2.2(b) below, and in any underwriting involved therein, all of such Registrable
        Securities as are specified in a written request or requests made by any Holder or Holders received by the Company within ten (10) days after such written notice from the Company is mailed or delivered. Such written request may specify all or a
        part of a Holder’s Registrable Securities.

     

    (b)          Underwriting. If the registration of which the Company gives notice is for a registered public offering involving an
        underwriting, the Company shall so advise the Holders as a part of the written notice given pursuant to Section 2.2(a)(i). In such event, the right of any Holder to registration pursuant to this Section 2.2 shall be conditioned upon such Holder’s
        participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting to the extent provided herein. All Holders proposing to distribute their securities through such underwriting shall (together with the
        Company and the Other Selling Stockholders other holders of securities of the Company with registration rights to participate therein distributing their securities through such underwriting) enter into an underwriting agreement in customary form
        with the representative of the underwriter or underwriters selected by the Company.

     

    Notwithstanding any other provision of this Section 2.2, if the underwriters advise the Company in writing that marketing factors require a
      limitation on the number of shares to be underwritten, the underwriters may (subject to the limitations set forth below) exclude all Registrable Securities from, or limit the number of Registrable Securities to be included in, the registration and
      underwriting. The Company shall so advise all holders of securities requesting registration, and the number of shares of securities that are entitled to be included in the registration and underwriting shall be allocated, as follows: (i) first, to
      the Company for securities being sold for its own account, (ii) second, to the Holders requesting to include Registrable Securities in such registration statement based on the pro rata percentage of Registrable Securities held by such Holders,
      assuming conversion and (iii) third, to the Other Selling Stockholders requesting to include Other Shares in such registration statement based on the pro rata percentage of Other Shares held by such Other Selling Stockholders, assuming conversion.
      Notwithstanding the foregoing, in no event shall the amount of securities of the Holders included in the offering be reduced below thirty percent (30%) of the total amount of securities included in such offering, unless such offering is the Company’s
      Initial Public Offering, in which case securities of the Holders may be excluded in their entirety if the underwriters make the determination described above and no Other Selling Stockholder’s securities are included in such offering.

    
      7

      
        
 

    

    If a person who has requested inclusion in such registration as provided above does not agree to the terms of any such underwriting, such
      person shall also be excluded therefrom by written notice from the Company or the underwriter. The Registrable Securities or other securities so excluded shall also be withdrawn from such registration. Any Registrable Securities or other securities
      excluded or withdrawn from such underwriting shall be withdrawn from such registration. If shares are so withdrawn from the registration and if the number of shares of Registrable Securities to be included in such registration was previously reduced
      as a result of marketing factors pursuant to Section 2.2(b), the Company shall then offer to all persons who have retained the right to include securities in the registration the right to include additional securities in the registration in an
      aggregate amount equal to the number of shares so withdrawn, with such shares to be allocated among the persons requesting additional inclusion, in the manner set forth above.

     

    (c)          Right to Terminate Registration. The Company shall have the right to terminate or withdraw any registration initiated by
        it under this Section 2.2 prior to the effectiveness of such registration whether or not any Holder has elected to include securities in such registration, and such registration will not count as a “registration” effected hereunder.

     

    2.3          Registration on Form S-3.

     

    (a)          Request for Form S-3 Registration. After its Initial Public Offering, the Company shall use its commercially reasonable
        efforts to qualify for registration on Form S-3 or any comparable or successor form or forms. After the Company has qualified for the use of Form S-3, in addition to the rights contained in the foregoing provisions of this Section 2 and subject to
        the conditions set forth in this Section 2.3, if the Company shall receive from a Holder or Holders of Registrable Securities holding in the aggregate not less than ten percent (10%) of the outstanding Registrable Securities a written request that
        the Company effect any registration on Form S-3 or any similar short form registration statement with respect to all or part of the Registrable Securities (such request shall state the number of shares of Registrable Securities to be disposed of
        and the intended methods of disposition of such shares by such Holder or Holders and whether the offering will be underwritten), the Company will take all such action with respect to such Registrable Securities as required by Section 2.1(a) (i) and
        2.1(a) (ii).

     

    (b)          Limitations on Form S-3 Registration. The Company shall not be obligated to effect, or take any action to effect, any such
        registration pursuant to this Section 2.3:

     

    (i)          In the
        circumstances described in either Sections 2.1 (b)(i), 2.1(b)(iii) or 2.1(b)(v);

     

    (ii)        If the
        Holders, together with the holders of any other securities of the Company entitled to inclusion in such registration, propose to sell Registrable Securities and such other securities (if any) on Form S-3 at an aggregate price to the public of less
        than $l,000,000; or

     

    (iii)        If, in a
        given six-month period, the Company has effected one (1) such registration in such period.

    
      8

      
        
 

    

    (c)          Deferral. The provisions of Section 2.1(c) shall apply to any registration pursuant to this Section 2.3.

     

    (d)        Underwriting. If the Holders of Registrable Securities requesting registration under this Section 2.3 intend to distribute
        the Registrable Securities covered by their request by means of an underwriting, the provisions of Section 2.1(e) shall apply to such registration. Notwithstanding anything contained herein to the contrary, registrations effected pursuant to this
        Section 2.3 shall not be counted as requests for registration or registrations effected pursuant to Section 2.1.

     

    2.4          Expenses of Registration. All Registration Expenses incurred in connection with
        registrations pursuant to Sections 2.1, 2.2 and 2.3 shall be borne by the Company; provided, however, that the Company shall not be
        required to pay for any expenses of any registration proceeding begun pursuant to Sections 2.1 and 2.3 if the registration request is subsequently withdrawn at the request of the Holders of a majority of the Registrable Securities to be registered
        or because a sufficient number of Holders shall have withdrawn so that the minimum offering conditions set forth in Sections 2.1 and 2.3 are no longer satisfied (in which case all participating Holders shall bear such expenses pro rata among each other based on the number of Registrable Securities requested to be so registered), unless the Holders of a majority of
        the Registrable Securities agree to forfeit their right to a demand registration pursuant to Section 2.1(a); provided, however, in the
        event that a withdrawal by the Holders is based upon material adverse information relating to the Company that is different from the information known or available (upon request from the Company or otherwise) to the Holders requesting registration
        at the time of their request for registration under Section 2.1, such registration shall not be treated as a counted registration for purposes of Section 2.1 hereof, even though the Holders do not bear the Registration Expenses for such
        registration. All Selling Expenses relating to securities registered on behalf of the Holders shall be borne by the holders of securities included in such registration pro rata among each other on the basis of the number of Registrable Securities so registered.

     

    2.5          Registration Procedures. In the case of each registration effected by the Company
        pursuant to Section 2, the Company will keep each selling Holder advised in writing as to the initiation of each registration and as to the completion thereof. At its expense, the Company will use its commercially reasonable efforts to:

     

    (a)          Prepare and
        file with the Commission a registration statement with respect to such Registrable Securities and cause such registration statement to become effective;

     

    (b)         Keep such
        registration effective for a period ending on the earlier of the date which is one hundred twenty (120) days from the effective date of the registration statement or such time as the Holder or Holders have completed the distribution described in
        the registration statement relating thereto; provided, however, that such one hundred twenty (120) day period shall be extended for a
        period of time equal to the period the Holder refrains, at the request of an underwriter of Common Stock (or other securities) of the Company, from selling any securities included in such registration;

     

    (c)          Prepare and
        file with the Commission such amendments and supplements to such registration statement and the prospectus used in connection with such registration statement as may be necessary to comply with the provisions of the Securities Act with respect to
        the disposition of all securities covered by such registration statement;

     

    (d)          Furnish such
        number of prospectuses, including any preliminary prospectuses, and other documents incident thereto, including any amendment of or supplement to the prospectus, as a Holder from time to time may reasonably request;

     

    
      9

      
        
 

    

    (e)          Register and
        qualify the securities covered by such registration statement under such other securities or Blue Sky laws of such jurisdictions as shall be reasonably requested by the Holders; provided, that the Company shall
        not be required in connection therewith or as a condition thereto to qualify to do business or to file a general consent to service of process in any such states or jurisdictions, unless the Company is already subject to service in such
        jurisdiction and except as may be required by the Securities Act;

     

    (f)          Notify each
        seller of Registrable Securities covered by such registration statement at any time when a prospectus relating thereto is required to be delivered under the Securities Act of the happening of any event as a result of which the prospectus included
        in such registration statement, as then in effect, includes an untrue statement of a material fact or omits to state a material fact required to be stated therein or necessary to make the statements therein not misleading or incomplete in light of
        the circumstances then existing, and following such notification promptly prepare and furnish to such seller a reasonable number of copies of a supplement to or an amendment of such prospectus as may be necessary so that, as thereafter delivered to
        the purchasers of such shares, such prospectus shall not include an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading or incomplete in light
        of the circumstances then existing;

     

    (g)          Provide a
        transfer agent and registrar for all Registrable Securities registered pursuant to such registration statement and a CUSIP number for all such Registrable Securities, in each case not later than the effective date of such registration;

     

    (h)         Promptly
        make available for inspection by the selling Holders, any underwriter(s) participating in any disposition pursuant to such registration statement, and any attorney or accountant or other agent retained by such underwriter or selected by the selling
        Holders, all financial and other records, pertinent corporate documents, and properties of the Company, and cause the Company’s officers, directors, employees, and independent accountants to supply all information reasonably requested by any such
        selling Holder, underwriter, attorney, accountant, or agent, in each case, as necessary or advisable to verify the accuracy of the information in such registration statement and to conduct appropriate due diligence in connection therewith;

     

    (i)          Notify each
        selling Holder, promptly after the Company receives notice thereof, of the time when such registration statement has been declared effective or a supplement to any prospectus forming part of such registration statement has been filed;

     

    (j)          After such
        registration statement becomes effective, notify each selling Holder of any request by the Commission that the Company amend or supplement such registration statement or prospectus;

     

    (k)          Cause all
        such Registrable Securities registered pursuant hereunder to be listed on a national securities exchange or trading system and each securities exchange on which similar securities issued by the Company are then listed; and

     

    (l)          In
        connection with any underwritten offering, enter into and perform its obligations under an underwriting agreement, in form reasonably necessary to effect the offer and sale of Common Stock, provided such underwriting agreement contains reasonable
        and customary provisions.

     

    In addition, the Company shall ensure that, at all times after any registration statement covering a public offering of securities of the
      Company under the Securities Act shall have become effective, its insider trading policy shall provide that the Company’s directors may implement a trading program under Rule 10b5- 1 of the Exchange Act, unless determined otherwise by the board of
      directors of the Company.

    
      10

      
        
 

    

    2.6          Indemnification.

     

    (a)          To the
        extent permitted by law, the Company will indemnify and hold harmless each Holder, each of its officers, directors and partners, legal counsel and accountants and each person controlling such Holder within the meaning of Section 15 of the
        Securities Act, with respect to which registration, qualification or compliance has been effected pursuant to this Section 2, and each underwriter, if any, and each person who controls within the meaning of Section 15 of the Securities Act any
        underwriter, against all expenses, claims, losses, damages and liabilities (or actions, proceedings or settlements in respect thereof) arising out of or based on: (i) any untrue statement (or alleged untrue statement) of a material fact contained
        or incorporated by reference in any prospectus, offering circular or other document (including any related registration statement, notification or the like) incident to any such registration, qualification or compliance, (ii) any omission (or
        alleged omission) to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading, or (iii) any violation (or alleged violation) by the Company of the Securities Act, any state securities
        laws or any rule or regulation thereunder applicable to the Company and relating to action or inaction required of the Company in connection with any offering covered by such registration, qualification or compliance, and the Company will reimburse
        each such Holder, each of its officers, directors, partners, legal counsel and accountants and each person controlling such Holder, each such underwriter and each person who controls any such underwriter, for any legal and any other expenses
        reasonably incurred in connection with investigating and defending or settling any such claim, loss, damage, liability or action; provided
        that the Company will not be liable in any such case to the extent that any such claim, loss, damage, liability, or action arises out of or is based on any untrue statement or omission based upon written information furnished to the Company by such
        Holder, any of such Holder’s officers, directors, partners, legal counsel or accountants, any person controlling such Holder, such underwriter or any person who controls any such underwriter, and stated to be specifically for use therein; and provided, further that, the indemnity agreement contained in this Section 2.6(a) shall not apply to amounts paid in settlement of any such
        loss, claim, damage, liability or action if such settlement is effected without the consent of the Company (which consent shall not be unreasonably withheld).

     

    (b)         To the
        extent permitted by law, each Holder will, if Registrable Securities held by such Holder are included in the securities as to which such registration, qualification or compliance is being effected, indemnify and hold harmless the Company, each of
        its directors, officers, partners, legal counsel and accountants and each underwriter, if any, of the Company’s securities covered by such a registration statement, each person who controls the Company or such underwriter within the meaning of
        Section 15 of the Securities Act, each other such Holder, and each of their officers, directors and partners, and each person controlling each other such Holder, against all claims, losses, damages and liabilities (or actions in respect thereof)
        arising out of or based on: (i) any untrue statement (or alleged untrue statement) of a material fact contained or incorporated by reference in any prospectus, offering circular or other document (including any related registration statement,
        notification, or the like) incident to any such registration, qualification or compliance, or (ii) any omission (or alleged omission) to state therein a material fact required to be stated therein or necessary to make the statements therein not
        misleading, and will reimburse the Company and such Holders, directors, officers, partners, legal counsel and accountants, persons, underwriters, or control persons for any legal or any other expenses reasonably incurred in connection with
        investigating or defending any such claim, loss, damage, liability or action, in each case to the extent, but only to the extent, that such untrue statement (or alleged untrue statement) or omission (or alleged omission) is made in such
        registration statement, prospectus, offering circular or other document in reliance upon and in conformity with written information furnished to the Company by such Holder and stated to be specifically for use therein; provided, however, that the obligations of such Holder hereunder shall not apply to amounts paid in settlement of any such claims, losses, damages or
        liabilities (or actions in respect thereof) if such settlement is effected without the consent of such Holder (which consent shall not be unreasonably withheld); and provided that in no event shall any
        indemnity under this Section 2.6 exceed the gross proceeds from the offering received by such Holder, except in the case of fraud or willful misconduct by such Holder.

    
      11

      
        
 

    

    (c)          Each party
        entitled to indemnification under this Section 2.6 (the “Indemnified Party”) shall give notice to the party required
        to provide indemnification (the “Indemnifying Party”) promptly after such Indemnified Party has actual knowledge of
        any claim as to which indemnity may be sought, and shall permit the Indemnifying Party to assume the defense of such claim or any litigation resulting therefrom; provided that counsel for the Indemnifying
        Party, who shall conduct the defense of such claim or any litigation resulting therefrom, shall be approved by the Indemnified Party (whose approval shall not be unreasonably withheld), and the Indemnified Party may participate in such defense at
        such party’s expense; and provided further that the failure of any Indemnified Party to give notice as provided herein shall not relieve
        the Indemnifying Party of its obligations under this Section 2.6, to the extent such failure is not prejudicial. No Indemnifying Party, in the defense of any such claim or litigation, shall, except with the consent of each Indemnified Party,
        consent to entry of any judgment or enter into any settlement that does not include as an unconditional term thereof the giving by the claimant or plaintiff to such Indemnified Party of a release from all liability in respect to such claim or
        litigation. Each Indemnified Party shall furnish such information regarding itself or the claim in question as an Indemnifying Party may reasonably request in writing and as shall be reasonably required in connection with defense of such claim and
        litigation resulting therefrom.

     

    (d)          If the
        indemnification provided for in this Section 2.6 is held by a court of competent jurisdiction to be unavailable to an Indemnified Party with respect to any loss, liability, claim, damage, or expense referred to herein, then the Indemnifying Party,
        in lieu of indemnifying such Indemnified Party hereunder, shall contribute to the amount paid or payable by such Indemnified Party as a result of such loss, liability, claim, damage, or expense in such proportion as is appropriate to reflect the
        relative fault of the Indemnifying Party on the one hand and of the Indemnified Party on the other in connection with the statements or omissions that resulted in such loss, liability, claim, damage, or expense as well as any other relevant
        equitable considerations. The relative fault of the Indemnifying Party and of the Indemnified Party shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission to state
        a material fact relates to information supplied by the Indemnifying Party or by the Indemnified Party and the parties’ relative intent, knowledge, access to information, and opportunity to correct or prevent such statement or omission. No person or
        entity will be required under this Section 2.6(d) to contribute any amount in excess of the gross proceeds from the offering received by such person or entity, except in the case of fraud or willful misconduct by such person or entity. No person or
        entity guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) will be entitled to contribution from any person or entity who or that was not guilty of such fraudulent misrepresentation.

     

    (e)          Notwithstanding

        the foregoing, to the extent that the provisions on indemnification and contribution contained in the underwriting agreement entered into in connection with the underwritten public offering are in conflict with the foregoing provisions, the
        provisions in the underwriting agreement shall control.

     

    2.7          Information by Holder. Each Holder of Registrable Securities shall furnish to the
        Company such information regarding such Holder and the distribution proposed by such Holder as the Company may reasonably request in writing and as shall be reasonably required in connection with any registration, qualification, or compliance
        referred to in this Section 2.

    
      12

      
        
 

    

    2.8          Restrictions on Transfer.

     

    (a)          The holder
        of each certificate representing Registrable Securities by acceptance thereof agrees to comply in all respects with the provisions of this Section 2.8. Each Holder agrees not to make any sale, assignment, transfer, pledge or other disposition of
        all or any portion of the Restricted Securities, or any beneficial interest therein, unless and until the transferee thereof has agreed in writing for the benefit of the Company to take and hold such Restricted Securities subject to, and to be
        bound by, the terms and conditions set forth in this Agreement, including, without limitation, this Section 2.8 and Section 2.10, and:

     

    (i)         There is
        then in effect a registration statement under the Securities Act covering such proposed disposition and the disposition is made in accordance with the registration statement; or

     

    (ii)        The Holder
        shall have given prior written notice to the Company of the Holder’s intention to make such disposition and shall have furnished the Company with a detailed description of the manner and circumstances of the proposed disposition, and, if requested
        by the Company, the Holder shall have furnished the Company, at the Holder’s expense, with (i) an opinion of counsel reasonably satisfactory to the Company to the effect that such disposition will not require registration of such Restricted
        Securities under the Securities Act or (ii) a “no action” letter from the Commission to the effect that the transfer
        of such securities without registration will not result in a recommendation by the staff of the Commission that action be taken with respect thereto, whereupon the holder of such Restricted Securities shall be entitled to transfer such Restricted
        Securities in accordance with the terms of the notice delivered by the Holder to the Company.

     

    (b)          Each
        certificate representing Registrable Securities shall (unless otherwise permitted by the provisions of this Agreement) be stamped or otherwise imprinted with a legend substantially similar to the following (in addition to any legend required under
        applicable state securities laws):

     

    THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED
      (THE “ACT”), OR UNDER THE SECURITIES LAWS OF CERTAIN STATES. THESE SECURITIES MAY NOT BE OFFERED, SOLD OR OTHERWISE
      TRANSFERRED, PLEDGED OR HYPOTHECATED EXCEPT AS PERMITTED UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS PURSUANT TO REGISTRATION OR AN EXEMPTION THEREFROM. THE ISSUER OF THESE SECURITIES MAY REQUIRE AN OPINION OF COUNSEL REASONABLY SATISFACTORY
      TO THE ISSUER THAT SUCH OFFER, SALE OR TRANSFER, PLEDGE OR HYPOTHECATION OTHERWISE COMPLIES WITH THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS.

     

    THE SECURITIES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE, INCLUDING A
      LOCK-UP PERIOD IN THE EVENT OF A PUBLIC OFFERING, AS SET FORTH IN AN INVESTORS’ RIGHTS AGREEMENT BY AND BETWEEN THE ISSUER AND THE ORIGINAL HOLDER OF THESE SECURITIES. A COPY OF SUCH AGREEMENT MAY BE OBTAINED UPON WRITTEN REQUEST TO THE SECRETARY OF
      THE ISSUER.

    
      13

      
        
 

    

    The Holders consent to the Company making a notation on its records and giving instructions to any transfer agent of the Restricted
      Securities in order to implement the restrictions on transfer established in this Section 2.8.

     

    (c)          The first
        legend referring to federal and state securities laws identified in Section 2.8(b) stamped on a certificate evidencing the Restricted Securities and the stock transfer instructions and record notations with respect to the Restricted Securities
        shall be removed and the Company shall issue a certificate without such legend to the holder of Restricted Securities if (i) those securities are registered under the Securities Act, or (ii) the holder provides the Company with an opinion of
        counsel reasonably acceptable to the Company to the effect that a sale or transfer of those securities may be made without registration or qualification.

     

    2.9          Rule 144 Reporting. With a view to making available the benefits of certain rules
        and regulations of the Commission that may permit the sale of the Restricted Securities to the public without registration, the Company agrees to use its commercially reasonable efforts to:

     

    (a)          Make and
        keep adequate current public information with respect to the Company available in accordance with Rule 144 under the Securities Act, at all times from and after ninety (90) days following the effective date of the first registration under the
        Securities Act filed by the Company for an offering of its securities to the general public;

     

    (b)          File with
        the Commission in a timely manner all reports and other documents required of the Company under the Securities Act and the Exchange Act at any time after it has become subject to such reporting requirements; and

     

    (c)          So long as a
        Holder owns any Restricted Securities, furnish to the Holder forthwith upon written request a written statement by the Company as to its compliance with the reporting requirements of Rule 144 (at any time from and after ninety (90) days following
        the effective date of the first registration statement filed by the Company for an offering of its securities to the general public), and of the Securities Act and the Exchange Act (at any time after it has become subject to such reporting
        requirements), a copy of the most recent annual or quarterly report of the Company, and such other reports and documents so filed as a Holder may reasonably request in availing itself of any rule or regulation of the Commission allowing a Holder to
        sell any such securities without registration.

     

    2.10        Market Stand-Off Agreement. If requested by the Company or an underwriter, each
        Holder shall not sell or otherwise transfer, make any short sale of, grant any option for the purchase of, or enter into any hedging or similar transaction with the same economic effect as a sale of, any Common Stock (or other securities) of the
        Company held by such Holder (other than those included in the registration) for such period of time as reasonably requested by the Company or such underwriter, but not to exceed one hundred eighty (180) days following the effective date of the
        registration statement for the initial public offering of the Company’s securities filed under the Securities Act (and for such additional period, if any, requested by the Company or an underwriter to accommodate regulatory restrictions on (i) the
        publication or other distribution of research reports and (ii) analyst recommendations and opinions, including, but not limited to, the restrictions contained in NASD Rule 2711(f)(4) or NYSE Rule 472(f)(4), or any successor provisions or amendments
        thereto). The obligations described in this Section 2.10 shall not apply to a registration relating solely to employee benefit plans on Form S-l or Form S-8 or similar forms that may be promulgated in the future, or a registration relating solely
        to a transaction on Form S-4 or similar forms that may be promulgated in the future. The Company may impose stop-transfer instructions and may stamp each such certificate with the second legend set forth in Section 2.8(b) with respect to the shares
        of Common Stock (or other securities) subject to the foregoing restriction until the end of such one hundred eighty (180) day (or other) period. Any discretionary waiver or termination of the restrictions of any or all of such agreements by the
        Company or the underwriters shall apply to all Holders subject to such agreements pro rata based on the number of shares subject to such agreements. Each Holder agrees to execute a market stand-off agreement with the underwriters in the offering in
        customary form consistent with the provisions of this section.

    
      14

      
        
 

    

     

    2.11        Delay of Registration. No Holder shall have any right to take any action to
        restrain, enjoin, or otherwise delay any registration as the result of any controversy that might arise with respect to the interpretation or implementation of this Section 2.

     

    2.12          Transfer or Assignment of Registration Rights. The rights to cause the Company to
        register securities granted to a Holder by the Company under this Section 2 may be transferred or assigned by a Holder only to a transferee or assignee that is (a) an affiliated entity (including affiliated venture capital funds) or a partner or
        former partner of the transferring Holder or (b) the transferee or assignee of not less than 10,000 shares of Registrable Securities (as presently constituted and subject to subsequent adjustments for stock splits, stock dividends, reverse stock
        splits, and the like); provided that (i) such transfer or assignment of Registrable Securities is effected in accordance with the terms
        of Section 2.8 and applicable securities laws, (ii) the Company is given written notice prior to said transfer or assignment, stating the name and address of the transferee or assignee and identifying the securities with respect to which such
        registration rights are intended to be transferred or assigned and (iii) the transferee or assignee of such rights assumes in writing the obligations of such Holder under this Agreement, including without limitation the obligations set forth in
        Section 2.10.

     

    2.13      Limitations on Subsequent Registration Rights. From and after the date of this
        Agreement, the Company shall not, without the prior written consent of (i) Holders holding a majority of the Registrable Securities, and (ii) both (a) the holders of a majority of the then-outstanding shares of Series E Preferred Stock and (b) each
        of the Major Investors, enter into any agreement with any holder or prospective holder of any securities of the Company giving such holder or prospective holder any registration rights the terms of which are senior to, or pari passu with, the registration rights granted to the Holders hereunder.

     

    2.14       Termination of Registration Rights. The right of any Holder to request registration
        or inclusion in any registration pursuant to Sections 2.1, 2.2 or 2.3 shall terminate upon and be of no further force or effect after the earliest to occur of: (a) five (5) years after the closing of the Company’s Initial Public Offering and (b)
        the consummation of a Liquidation Event.

     

    SECTION 3.

    

      INFORMATION COVENANTS OF THE COMPANY

     

    3.1          Basic Financial Information and Inspection Rights.

     

    (a)          Basic Financial Information. The Company will furnish to each Holder who owns at least 10,000 Shares and/or Conversion
        Stock (as presently constituted and subject to subsequent adjustments for stock splits, stock dividends, reverse stock splits, and the like) as soon as practicable after the end of each fiscal year of the Company, and in any event within one
        hundred twenty (120) days after the end of each fiscal year of the Company, a consolidated balance sheet of the Company and its subsidiaries, if any, as at the end of such fiscal year, and consolidated statements of income and cash flows of the
        Company and its subsidiaries, if any, for such year, prepared in accordance with U.S. generally accepted accounting principles consistently applied, and audited and certified by independent public accountants of recognized national or regional
        standing selected by the Company.

     

    (b)          Additional Financial Information. In addition to the annual audited financial statements described in Section 3.1(a), the
        Company will furnish to each Holder who owns at least 50,000 Shares and/or Conversion Stock (as presently constituted and subject to subsequent adjustments for stock splits, stock dividends, reverse stock splits, and the like):

    
      15

      
        
 

    

    (i)          as soon as
        practicable after the end of the first, second and third quarterly accounting periods in each fiscal year of the Company, and in any event within forty-five (45) days after the end of the first, second, and third quarterly accounting periods in
        each fiscal year of the Company, (A) an unaudited consolidated balance sheet of the Company and its subsidiaries, if any, as of the end of each such quarterly period, (B) unaudited consolidated statements of income and cash flows of the Company and
        its subsidiaries, if any, for such period, prepared in accordance with U.S. generally accepted accounting principles consistently applied, subject to changes resulting from normal year-end audit adjustments and (C) an up-to-date table showing the
        Company’s capitalization;

     

    (ii)         as soon as
        practicable after the end of each month, and in any event within thirty (30) days after the end of such month, (A) an unaudited consolidated balance sheet of the Company and its subsidiaries, if any, as of the end of such month, and (B) unaudited
        consolidated statements of income and cash flows of the Company and its subsidiaries, if any, for such month, prepared in accordance with U.S. generally accepted accounting principles consistently applied, subject to changes resulting from normal
        year-end audit adjustments;

     

    (iii)         as soon
        as practicable, but in any event at least thirty (30) days prior to the end of each fiscal year, a capital and operating budget for the next fiscal year; and

     

    (iv)         such other
        information as may be determined by the board of directors of the Company at such times as may be determined by the board of directors of the Company.

     

    (c)          Inspection Rights. The Company will afford to each Holder who owns at least 50,000 Shares and/or Conversion Stock (as
        presently constituted and subject to subsequent adjustments for stock splits, stock dividends, reverse stock splits, and the like), reasonable access during normal business hours and with reasonable advance notification to the Company, to the
        Company’s facilities, books and records and personnel. Holders may exercise their rights under this Section 3.1(c) only for purposes reasonably related to their interests under this Agreement and related agreements. The rights granted pursuant to
        this Section 3.1(c) may not be assigned or otherwise conveyed by the Holders or by any subsequent transferee of any such rights without the prior written consent of the Company.

     

    3.2         Confidentiality. Anything in this Agreement to the contrary notwithstanding, no
        Holder by reason of this Agreement shall have access to any trade secrets or classified information of the Company. The Company shall not be required to comply with any information rights of Section 3 in respect of any Holder whom the Company
        reasonably determines to be a competitor or an officer, employee, director or holder of more than ten percent (10%) of a competitor. Each Holder acknowledges that the information received by such Holder pursuant to this Agreement may be
        confidential and for its use only, and agrees that it will not use such confidential information in violation of the Exchange Act or reproduce, disclose or disseminate such information to any other person (other than its employees or agents having
        a need to know the contents of such information, and its attorneys), except in connection with the exercise of rights under this Agreement, unless the Company has made such information available to the public generally or such Holder is required to
        disclose such information by a governmental authority; provided, however, that a Holder may disclose confidential information to any
        existing or prospective affiliate, partner, member, stockholder or other wholly owned subsidiary of such Holder in the ordinary course of business, provided that such Holder informs such person or entity that such information is confidential and such person or entity is obligated to maintain the confidentiality of such information.

    
      16

      
        
 

    

     

    3.3          Termination of Covenants. The covenants set forth in this Section 3 shall terminate
        upon and be of no further force and effect after the earliest to occur of: (a) the closing of the Company’s Initial Public Offering; (b) the consummation of a Liquidation Event or Deemed Liquidation Event; and (c) the Reporting Date.

     

    SECTION 4.

      

      RIGHT OF FIRST REFUSAL

     

    4.1          Right of First Refusal to Significant Holders. The Company hereby grants to each
        Holder who owns at least 10,000 Shares or Conversion Stock (as presently constituted and subject to subsequent adjustments for stock splits, stock dividends, reverse stock splits and the like) (the “Significant Holders”), the right of first refusal to purchase its pro rata share of New Securities (as
        defined in this Section 4.1(a)) which the Company may, from time to time, propose to sell and issue after the date of this Agreement. A Significant Holder’s pro rata share, for purposes of this right of first refusal, is equal to the ratio of (a) the number of shares of Common Stock owned by such Significant Holder immediately prior to the issuance of New Securities
        (assuming full conversion of the Shares and full conversion or exercise of all outstanding convertible securities, rights, options and warrants held by said Significant Holder) to (b) the total number of shares of Common Stock outstanding
        immediately prior to the issuance of New Securities (assuming full conversion of the Shares and full conversion or exercise of all outstanding convertible securities, rights, options and warrants). Each Significant Holder shall have a right of
        over-allotment such that if any Significant Holder fails to exercise its right hereunder to purchase its pro rata share of New Securities, the other Significant Holders may purchase the non-purchasing Significant Holder’s portion on a pro rata
        basis. This right of first refusal shall be subject to the following provisions:

     

    (a)          “New Securities” shall mean any capital stock (including Common Stock and/or Preferred Stock) of the Company whether now
        authorized or not, and rights, convertible securities, options or warrants to purchase such capital stock, and securities of any type whatsoever that are, or may become, exercisable or convertible into capital stock; provided that the term “New Securities”
        does not include:

     

    (i)           the
        Conversion Stock and the Series F Preferred Stock to be issued and sold pursuant to Section 2.2 of the Purchase Agreement;

     

    (ii)          securities
        issued or issuable to officers, employees, directors, consultants, placement agents, and other service providers of the Company (or any subsidiary) pursuant to stock grants, option plans, purchase plans, warrants, agreements or other employee stock
        incentive programs or arrangements approved by the board of directors of the Company (including a majority of the Preferred Directors then in office);

     

    (iii)         securities

        issued or issuable upon the exercise, exchange, adjustment or conversion of any convertible or exercisable securities outstanding as of this date of this Agreement;

     

    (iv)         securities
        issued or issuable as a dividend or distribution on Preferred Stock of the Company or pursuant to any event for which adjustment is made pursuant to paragraph 3.4(e), 3.4(f) or 3.4(g) of the Certificate of Incorporation;

     

    (v)          securities
        offered or issued pursuant to a bona fide, firm commitment underwritten public offering pursuant to a registration statement filed under the Securities Act;

    
      17

      
        
 

    

     

    (vi)       securities
        issued or issuable pursuant to the acquisition of another corporation by the Company by merger, purchase of substantially all of the assets or other reorganization or to a joint venture agreement, provided, that such issuances are approved by the board of directors of the Company (including a majority of the Preferred Directors then in office);

     

    (vii)       securities
        issued or issuable to banks, equipment lessors or other financial institutions pursuant to a commercial leasing or debt financing transaction approved by the board of directors of the Company (including a majority of the Preferred Directors then in
        office);

     

    (viii)      securities
        issued or issuable in connection with sponsored research, collaboration, technology license, development, OEM, marketing or other similar agreements or strategic partnerships approved by the board of directors of the Company (including a majority
        of the Preferred Directors then in office);

     

    (ix)         securities
        of the Company which are otherwise excluded by the affirmative vote or consent of the holders of a majority of the shares of Preferred Stock of the Company then outstanding (voting together as a single class and not as separate series, and on an
        as-converted basis, and including both (A) the holders of a majority of the then-outstanding shares of Series F Preferred Stock and Series E Preferred Stock (voting together as a single class and not as separate series, and on an as-converted
        basis) and (B) each of the Major Investors); and

     

    (x)          any right,
        option or warrant to acquire any security convertible into the securities excluded from the definition of New Securities pursuant to subsections (i) through (x) above.

     

    (b)          In the event
        the Company proposes to undertake an issuance of New Securities, it shall give each Significant Holder written notice of its intention, describing the type of New Securities, and their price and the general terms upon which the Company proposes to
        issue the same. Each Significant Holder shall have twenty (20) days after any such notice is mailed or delivered to agree to purchase such Holder’s pro rata share of such New Securities and to indicate whether such Significant Holder desires to exercise its over-allotment option, for the price and upon the terms specified in the notice by giving written notice to the Company,
        in substantially the form attached as Schedule 1, and stating therein the quantity of New Securities to be purchased.

     

    (c)          In the event
        the Significant Holders fail to exercise fully the right of first refusal and over-allotment right, if any, within said twenty (20) day period (the “Election Period”), the Company shall have ninety (90) days thereafter to sell or enter into an agreement (pursuant to which the sale of New Securities covered thereby shall be closed, if at all, within ninety (90)
        days from the date of said agreement) to sell that portion of the New Securities with respect to which the Significant Holders’ right of first refusal option set forth in this Section 4.1 was not exercised, at a price and upon terms no more
        favorable to the purchasers thereof than specified in the Company’s notice to Significant Holders delivered pursuant to Section 4.1(b). In the event the Company has not sold within such ninety (90) day period following the Election Period, or such
        ninety (90) day period following the date of said agreement, the Company shall not thereafter issue or sell any New Securities, without first again offering such securities to the Significant Holders in the manner provided in this Section 4.1.

     

    4.2         Termination of Covenants. The covenants set forth in this Section 4 shall terminate
        upon and be of no further force and effect after the earliest to occur of: (a) the closing of the Company’s Initial Public Offering and (b) the consummation of a Liquidation Event or Deemed Liquidation Event.

    
      18

      
        
 

    

    SECTION 5.

      

      BOARD OF DIRECTORS AND STOCKHOLDERS MATTERS

     

    5.1          Board Meetings. Meetings of the board of directors of the Company shall take place
        at least five times per calendar year, unless otherwise agreed by a vote of the majority of the directors, including the approval of a majority of the Preferred Directors.

     

    5.2         Directors and Officers Insurance. The Company shall maintain a policy or policies of
        directors and officers liability insurance providing for at least $5,000,000 in coverage on terms and conditions reasonably acceptable to a majority of the board of directors of the Company (including the approval of a majority of the Preferred
        Directors). In the event the Company merges with another entity and is not the surviving corporation proper provisions shall be made so that successors of the Company assume Company’s obligations with respect to indemnification of directors. In the
        event the Company transfers all of its assets, proper provisions shall be made for continued indemnification of directors.

     

    5.3          Matters Requiring Board Approval. So long as any shares of the Company’s Preferred
        Stock remain outstanding, the Company shall not, without first obtaining the approval of the board of directors of the Company:

     

    (a)          make any
        loan or advance to, or own any stock or other securities of, any subsidiary or other corporation, partnership, or other entity unless it is wholly owned by the Company;

     

    (b)          make any
        loan or advance to any person, including, any employee or director, except advances and similar expenditures in the ordinary course of business or under the terms of an employee stock or option plan approved by the board of directors of the
        Company;

     

    (c)          guarantee
        any indebtedness except for trade accounts of the Company or any subsidiary arising in the ordinary course of business;

     

    (d)          make any
        investment other than investments in prime commercial paper, money market funds, certificates of deposit in any United States bank having a net worth in excess of $100,000,000 or obligations issued or guaranteed by the United States of America, in
        each case having a maturity not in excess of two years;

     

    (e)          incur any
        aggregate indebtedness in excess of $100,000 that is not already included in a budget approved by the board of directors of the Company, other than trade credit incurred in the ordinary course of business;

     

    (f)           enter into
        or be a party to any transaction with any director, officer or employee of the Company or any “associate” (as defined
        in Rule 12b-2 promulgated under the Exchange Act) of any such person;

     

    (g)          change the
        principal business of the Company, enter new lines of business, or exit the current line of business;

     

    (h)          sell,
        transfer, license as licensor, pledge or encumber technology or intellectual property, other than licenses granted in the ordinary course of business;

     

    (i)           make any
        capital expenditure in excess of $50,000 (individually, or in the aggregate, for a series of related capital expenditures);

    
      19

      
        
 

    

    (j)           commit the
        Company to enter into a joint venture, license agreement, or exclusive marketing or other distribution agreement with respect to the Company’s products; or

    

    

    (k)          hire, fire,
        or change the compensation of the executive officers, including approving options plans or grants.

     

    5.4          Matters Requiring Approval by the Major Investors. So long as any shares of Series F
        Preferred Stock or Series E Preferred Stock remain outstanding:

     

    (a)          in addition
        to any other stockholder approval required by the Certificate of Incorporation or applicable law, the Company shall not, without first obtaining the approval of each of the Major Investors:

     

    (i)          effect or
        consent to any Liquidation Event (as defined in the Certificate of Incorporation), unless such Liquidation Event would constitute a Threshold Event;

     

    (ii)         effect or
        consent to any Deemed Liquidation Event (as defined in the Certificate of Incorporation), unless such Deemed Liquidation Event would constitute a Threshold Event;

     

    (iii)        change the
        Company’s principal line or lines of business;

     

    (iv)         amend the
        Company’s existing stock option plan or approve any new equity incentive plan;

     

    (v)          effect a
        redemption pursuant to Article III, Section 3.7 of the Certificate of Incorporation;

     

    (vi)         shorten or
        waive the notice provisions set forth in Article III, Section 3.4(h) of the Certificate of Incorporation;

     

    (vii)      authorize
        any offering of the Company’s Common Stock to the public unless the price of the Common Stock in such public offering is at least $16.0215 per share (as adjusted for any stock splits, stock dividends, combinations, subdivisions, recapitalizations
        or the like and before deduction of underwriters’ commissions and expenses); or

     

    (viii)      permit or
        agree to do any of the foregoing.

     

    (b)          In addition
        to any other stockholder approval required by the Certificate of Incorporation or applicable law, the Company shall not, without first obtaining the approval of a majority of the Major Investors, create or authorize the creation of or issue or
        obligate itself to issue shares of, any other security convertible into or exercisable for any equity security, having rights, preferences or privileges senior to or on parity with the Series F Preferred Stock, Series E-1 Preferred Stock, Series
        E-2 Preferred Stock, Series E-3 Preferred Stock or Series E-2A Preferred Stock.

     

    (c)          In addition
        to any other stockholder approval required by the Certificate of Incorporation of applicable law, the treatment of any particular transaction or series of related transactions as a Deemed Liquidation Event (as defined in the Certificate of
        Incorporation) may not be waived without the vote or written consent of each of the Major Investors.

     

    (d)          In addition
        to any other stockholder approval required by the Certificate of Incorporation of applicable law, the Automatic Conversion Event described in Section 3.4(b) (ii) of the Certificate of Incorporation shall require the written request of each of the
        Major Investors.

    
      20

      
        
 

    

    (e)          So long as
        any shares of Series F Preferred Stock remain outstanding, in addition to any other stockholder approval required by the Certificate of Incorporation or applicable law, the Company shall not, without first obtaining the approval of each of the
        Major Investors that hold shares of Series F Preferred Stock:

     

    (i)          reclassify,
        alter or amend any existing security that is junior to or on parity with the Series F Preferred Stock, if such reclassification, alteration or amendment would render such other security senior to or on parity with the Series F Preferred Stock; or

     

    (ii)         amend or
        waive any of the rights, preferences or privileges of the Series F Preferred Stock in the Certificate of Incorporation so as to adversely affect the Series F Preferred Stock; provided that the creation or
        authorization of one or more new series of Preferred Stock that is senior to or pari passu with the Series F Preferred Stock with respect to the distribution of assets on the liquidation, dissolution or winding up of the Company, the payment of
        dividends and/or rights of redemption shall not be deemed to adversely affect the Series F Preferred Stock.

     

    (f)          So long as
        any shares of Series E Preferred Stock remain outstanding, in addition to any other stockholder approval required by the Certificate of Incorporation or applicable law, the Company shall not, without first obtaining the approval of each of the
        Major Investors that hold shares of Series E Preferred Stock:

     

    (i)          reclassify,
        alter or amend any existing security that is junior to or on parity with the Series E-1 Preferred Stock, Series E-2 Preferred Stock, Series E-3 Preferred Stock or Series E-2A Preferred Stock, if such reclassification, alteration or amendment would
        render such other security senior to or on parity with any such series of Preferred Stock; or

     

    (ii)          amend or
        waive any of the rights, preferences or privileges of the Series E Preferred Stock in the Certificate of Incorporation so as to adversely affect the Series E Preferred Stock; provided that the creation or
        authorization of one or more new series of Preferred Stock that is senior to or pari passu with the Series E Preferred Stock with respect to the distribution of assets on the liquidation, dissolution or winding
        up of the Company, the payment of dividends and/or rights of redemption shall not be deemed to adversely affect the Series E Preferred Stock.

     

    5.5         FCPA. The Company represents that it shall not (and shall not permit any of its
        subsidiaries or affiliates or any of its or their respective directors, officers, managers, employees, independent contractors, representatives or agents acting on behalf of the Company to) promise, authorize or make any payment to, or otherwise
        contribute any item of value to, directly or indirectly, any third party, including any Non-U.S. Official (as (as such term is defined in the U.S. Foreign Corrupt Practices Act of 1977, as amended (the “FCPA”)), in each case, in violation of the FCPA, the U.K. Bribery Act, or any other applicable anti-bribery or anti-corruption law. The Company further represents that it shall (and shall cause each of its
        subsidiaries and affiliates to) cease all of its or their respective activities, as well as remediate any actions taken by the Company, its subsidiaries or affiliates, or any of their respective directors, officers, managers, employees, independent
        contractors, representatives or agents acting on behalf of the Company in violation of the FCPA, the U.K. Bribery Act, or any other applicable anti-bribery or anti-corruption law. The Company further represents that it shall (and shall cause each
        of its subsidiaries and affiliates to) maintain systems of internal controls (including, but not limited to, accounting systems, purchasing systems and billing systems) to ensure compliance with the FCPA, the U.K. Bribery Act, or any other
        applicable anti-bribery or anti-corruption law. Upon request, the Company agrees to provide  responsive information and/or certifications concerning its compliance with applicable anti-corruption laws. The Company shall promptly notify each
        Investor if the Company becomes aware of any enforcement action against the Company related to the FCPA or any other anti-corruption law. The Company shall, and shall cause any direct or indirect subsidiary or entity controlled by it, whether now
        in existence or formed in the future, to comply with the FCPA. The Company shall use its commercially reasonable efforts to cause any direct or indirect subsidiary, whether now in existence or formed in the future, to comply in all material
        respects with all applicable laws.

    
      21

      
        
 

    

    5.6         Termination of Covenants. The covenants set forth in this Section 5 shall terminate
        upon and be of no further force and effect after the earliest to occur of: (a) the closing of the Company’s Initial Public Offering and (b) the consummation of a Liquidation Event or Deemed Liquidation Event.

     

    SECTION 6.

      

      EMPLOYEE MATTERS

     

    6.1        Employee Proprietary Information Agreements. Each current and former employee and
        consultant with access to Company confidential information/trade secrets will enter into a non-disclosure and proprietary rights assignment agreement in a form reasonably acceptable to the Investors.

     

    6.2         Key Person Insurance. The Company shall maintain a life insurance policy on the life
        of Derek Maetzold for so long as he remains an employee of the Company in an amount of at least $1,000,000 and otherwise satisfactory to the board of directors of the Company (including the approval of a majority of the Preferred Directors), with
        the proceeds of such policy payable to the Company.

     

    6.3          Employee Stock. Unless otherwise approved by the board of directors of the Company
        (including a majority of the Preferred Directors then in office), all future employees and consultants of the Company who purchase, receive options to purchase, or receive awards of shares of the Company’s capital stock after the date hereof shall
        be required to execute restricted stock or option agreements, as applicable, providing for (i) vesting of shares over a four (4) year period, with the first twenty-five percent (25%) of such shares vesting following twelve (12) months of continued
        employment or service, and the remaining shares vesting in equal monthly installments over the following thirty-six (36) months, and (ii) a market stand-off provision substantially similar to that in Section 2.10. In addition, unless otherwise
        approved by the board of directors of the Company (including a majority of the Preferred Directors then in office), the Company shall retain a “right of first refusal” on transfers of shares of the Company’s capital stock by all (i) future
        employees and consultants of the Company until the Company’s Initial Public Offering and shall have the right to repurchase unvested shares held by such employees or consultants at the lower of cost or fair market value upon termination of
        employment or services of such holder of restricted stock or shares issued upon exercise of options and (ii) existing employees of the Company until the Company’s Initial Public Offering and shall have the right to repurchase unvested shares held
        by such employees at cost upon termination of employment of such holder of restricted stock or shares issued upon exercise of options.

     

    6.4         Termination of Covenants. The covenants set forth in this Section 6 shall terminate
        upon and be of no further force and effect after the earliest to occur of: (a) the closing of the Company’s Initial Public Offering and (b) the consummation of a Liquidation Event or Deemed Liquidation Event.

     

    SECTION 7.

      

      MISCELLANEOUS

     

    7.1          Amendment. Except as expressly provided herein, neither this Agreement nor any term
        hereof may be amended, waived, discharged or terminated other than by a written instrument referencing this Agreement and signed by the Company and the Holders holding a majority of the Registrable Securities (excluding any of such shares that have
        been sold to the public or pursuant to Rule 144) and each of the Major Investors. Any such amendment, waiver, discharge or termination effected in accordance with this paragraph shall be binding upon each Holder and each future holder of such
        securities of Holder. Each Holder acknowledges that by the operation of this paragraph, the Holders and Major Investors specified above will have the right and power to diminish or eliminate all rights of such Holder under this Agreement. By
        execution of this Agreement, the undersigned, on behalf of the undersigned and all Significant Holders, waive any rights of first refusal pursuant to Section 4 of the Prior Agreement, including any rights relating to notice thereof, with respect to
        the Company’s proposed offer and sale of Series F Preferred Stock and all shares of Common Stock issuable upon conversion of such Preferred Stock.

    
      22

      
        
 

    

    7.2          Notices. All notices and other communications required or permitted hereunder shall
        be in writing and shall be mailed by registered or certified mail, postage prepaid, sent by facsimile or electronic mail, or otherwise delivered by hand, messenger or courier service addressed:

     

    (a)          if to an
        Investor, to the Investor’s address, facsimile number or electronic mail address as shown on Exhibit A hereto, as may be updated in accordance with
        the provisions hereof;

     

    (b)         if to any
        Holder, to such address, facsimile number or electronic mail address as shown in the Company’s records, or, until any such Holder so furnishes an address, facsimile number or electronic mail address to the Company, then to the address, facsimile
        number or electronic mail address of the last holder of such shares for which the Company has contact information in its records; or

     

    (c)         if to the
        Company, to the attention of the Chief Executive Officer of the Company at 2014 San Miguel Drive, Friendswood, Texas 77546, or at such other address as the Company shall have furnished to the Holders, with a copy to Christopher J. Ozburn, Streusand
        Landon & Ozburn, LLP, 811 Barton Springs Road, Suite 811, Austin, Texas 78704.

     

    With respect to any notice given by the Company under any provision of the Delaware General Corporation Law, the Company’s Certificate of
      Incorporation or bylaws or this Agreement, each Holder agrees that such notice may be given by facsimile or by electronic mail.

     

    Each such notice or other communication shall for all purposes of this Agreement be treated as effective or having been given (i) if
      delivered by hand, messenger or courier service, when delivered, or (ii) if sent by mail, upon its receipt, or (iii) if sent by facsimile or electronic mail, when sent, if sent during normal business hours of the recipient, and if not sent during
      normal business hours, then on the recipient’s next business day.

     

    7.3          Governing Law. This Agreement shall be governed in all respects by the internal laws
        of the State of Delaware as applied to agreements entered into among Delaware residents to be performed entirely within Delaware, without regard to principles of conflicts of law.

     

    7.4          Successors and Assigns. This Agreement shall inure to the benefit of, and be binding
        upon, the successors, assigns, heirs, executors and administrators of the parties hereto.

     

    7.5        Entire Agreement. This Agreement and the exhibits hereto amend and restate the Prior
        Agreement and constitute the full and entire understanding and agreement among the parties with respect to the subject matter hereof and supersede all prior agreements and understandings between or among any of the parties with respect to the
        subject matter hereof, including, without limitation, the Prior Agreement. No party hereto shall be liable or bound to any other party in any manner with regard to the subjects hereof or thereof by any warranties, representations or covenants
        except as specifically set forth herein.

    
      23

      
        
 

    

     

    7.6         Delays or Omissions. Except as expressly provided herein, no delay or omission to
        exercise any right, power or remedy accruing to any party to this Agreement upon any breach or default of any other party under this Agreement shall impair any such right, power or remedy of such non-defaulting party, nor shall it be construed to
        be a waiver of any such breach or default, or an acquiescence therein, or of or in any similar breach or default thereafter occurring, nor shall any waiver of any single breach or default be deemed a waiver of any other breach or default
        theretofore or thereafter occurring. Any waiver, permit, consent or approval of any kind or character on the part of any party of any breach or default under this Agreement, or any waiver on the part of any party of any provisions or conditions of
        this Agreement, must be in writing and shall be effective only to the extent specifically set forth in such writing. All remedies, either under this Agreement or by law or otherwise afforded to any party to this Agreement, shall be cumulative and
        not alternative.

     

    7.7         Severability. If any provision of this Agreement becomes or is declared by a court
        of competent jurisdiction to be illegal, unenforceable or void, portions of such provision, or such provision in its entirety, to the extent necessary, shall be severed from this Agreement, and such court will replace such illegal, void or
        unenforceable provision of this Agreement with a valid and enforceable provision that will achieve, to the extent possible, the same economic, business and other purposes of the illegal, void or unenforceable provision. The balance of this
        Agreement shall be enforceable in accordance with its terms.

     

    7.8        Titles and Subtitles. The titles and subtitles used in this Agreement are used for
        convenience only and are not to be considered in construing or interpreting this Agreement. All references in this Agreement to sections, paragraphs and exhibits shall, unless otherwise provided, refer to sections and paragraphs hereof and exhibits
        attached hereto.

     

    7.9          Counterparts. This Agreement may be executed in any number of counterparts, each of
        which shall be enforceable against the parties that execute such counterparts, and all of which together shall constitute one instrument.

     

    7.10       Telecopy Execution and Delivery. A facsimile, telecopy or other reproduction of this
        Agreement may be executed by one or more parties hereto and delivered by such party by facsimile or any similar electronic transmission device pursuant to which the signature of or on behalf of such party can be seen. Such execution and delivery
        shall be considered valid, binding and effective for all purposes. At the request of any party hereto, all parties hereto agree to execute and deliver an original of this Agreement as well as any facsimile, telecopy or other reproduction hereof.

     

    7.11        Further Assurances. Each party hereto agrees to execute and deliver, by the proper
        exercise of its corporate, limited liability company, partnership or other powers, all such other and additional instruments and documents and do all such other acts and things as may be necessary to more fully effectuate this Agreement.

     

    
      24

      
        

    

    
    7.12        Aggregation of Stock. All securities held or acquired by affiliated entities
        (including affiliated venture capital funds) or persons shall be aggregated together for purposes of determining the availability of any rights under this Agreement.

     

    (signature pages follow)

    
      25

      
        
 

    

    

    

    The parties hereto are signing this Fifth Amended and Restated Investors’ Rights Agreement as of the date stated in the introductory clause,

     

    
      	 	
              CASTLE BIOSCIENCES, INC. 

              a Delaware corporation 

            
	 	 	 
	 	By:	/s/ Derek Maetzold
	 	 	Derek Maetzold
	 	 	President and Chief Executive Officer

    

    

    
       

      

      (Castle Biosciences, Inc. Fifth Amended and Restated Investors’ Rights Agreement)

      
        
          
 

      

    

     
    
      	
               

            	INVESTOR:
	 	 
	 	INDUSTRY VENTURES HEALTHCARE, LLC
	 	
	
               

            	
              By:

            	
              Industry Ventures Management VII, LLC

            
	
               

            	its Manager
	
               

            		
	
               

            	By:	/s/ Victor Hwang  
	 	 	Victor Hwang, Member

    

     

     (Castle Biosciences, Inc. Fifth Amended and Restated Investors’ Rights Agreement)

    
      
        
 

    

     
      
        	
                 

              	INVESTOR:
	 	 
	 	SOFINNOVA HEALTHQUEST PARTNERS, L.P.
	 	
	
                 

              	
                By:

              	Healthquest Venture Management, L.L.C.
	
                 

              	its General Partner
	
                 

              		
	
                 

              	By:	/s/ Garheng Kong   
	 	 	Garheng Kong, its Managing Member

      

    

    

    

          (Castle Biosciences, Inc. Fifth Amended and Restated Investors’ Rights Agreement)

    
      
        
 

    

     
      
        	
                 

              	INVESTORS:
	
                 

              	
                 

              	
                 

              
	
                 

              	FARVIEW MANAGEMENT CO. L.P.
	
                 

              	
                 

              	
                 

              
	 	By:	 /s/ Joe C. Cook Jr. 
	 	
                Name:Joe C. Cook Jr.

                Its: General Partner 

              

      

    

     
    
      	
               

            	MGC CASTLE, LLC
	
               

            	
               

            	
               

            
	
               

            	
              By:

            	/s/ Joe C. Cook Jr.  
	
               

            	
              Name: Joe C. Cook Jr.

              Its: President

            

    

    

      
        		MGC VENTURE PARTNERS 2013, L.P.
	 	 	
                 

              
		By:	MCC Venture Partners 2013 GP, LLC
		its General Partner 
	 	 
		By:	/s/ Joe C. Cook Jr. 
		Name: Joe C. Cook Jr.
		Its: Managing Partner

      

      

    

    (Castle Biosciences, Inc. Fifth Amended and Restated Investors’ Rights Agreement)

  
    
      
 

  

       
    
      	
               

            	INVESTORS:
	
               

            	
               

            
	
               

            	/s/ Joe Cook, Jr.
	
               

            	Joe Cook, Jr.
	
               

            	
               

            
	
               

            	 
	
               

            	Jamie L. Dingley
	
               

            	
               

            
	
               

            	
               

            
	
               

            	
              Tobin W. Juvenal

            
	
               

            	
               

            
	 	 
	
               

            	Susan Juvenal
	
               

            	
               

            
	
               

            	
               

            
	
               

            	Gregory J. Lausier
	
               

            	
               

            
	
               

            	
               

            
	
               

            	Derek J. Maetzold
	
               

            	
               

            
	
               

            	/s/ Beth A.
                Smith  
	
               

            	Beth A. Smith
	
               

            	
               

            
	
               

            	
              /s/ Byron W. Smith 

            
	
               

            	Byron W. Smith
	
               

            	
               

            
	
               

            	
               

            
	
               

            	Thomas P. Sullivan

       

    (Castle Biosciences, Inc. Fifth Amended and Restated Investors’ Rights Agreement)

    
      
        
 

    

  

  
    
      	
               

            	INVESTOR:
	
               

            	
               

            	
               

            
	
               

            	BIOBRIT, LLC
	
               

            	
               

            	
               

            
	 	By:	 /s/ Daniel M. Bradbury  
	 	
              Name: Daniel M. Bradbury

              Its: Managing Member

            

    

     

     (Castle Biosciences, Inc. Fifth Amended and Restated Investors’ Rights Agreement)

    
      
        
 

    

    

    
      	
               

            	INVESTOR:
	
               

            	
               

            	
               

            
	
               

            	LONGFELLOW VENTURE PARTNERS I, LLC
	
               

            	
               

            	
               

            
	 	By:	 /s/ Meredith Clark Shachay
	 	
              Name: Meredith Clark Shachay

              Its: President

            

    

    

    

    (Castle Biosciences, Inc. Fifth Amended and Restated Investors’ Rights Agreement) 

    
      
        
 

    

    

    
      	
               

            	INVESTOR:
	
               

            	
               

            	
               

            
	
               

            	PELMEA LIMITED PARTNERSHIP
	
               

            	
               

            	
               

            
	 	By:	/s/ Meredith Clark Shachay
	 	
              Name: Meredith Clark Shachay

              Its: Manager

            

    

     

    (Castle Biosciences, Inc. Fifth Amended and Restated Investors’ Rights Agreement) 

    
      
        
 

    

     
      
        	
                 

              	INVESTOR:
	
                 

              	
                 

              	
                 

              
	
                 

              	KOLTERMAN FAMILY TRUST
	
                 

              	
                 

              	
                 

              
	 	By:	/s/ Orville G. Kolterman
	 		Orville G. Kolterman, Trustee

      

    

    

    

    (Castle Biosciences, Inc. Fifth Amended and Restated Investors’ Rights Agreement) 

    
      
        
 

    

    
      
        	
                 

              	INVESTOR:
	
                 

              	
                 

              	
                 

              
	
                 

              	BONNIE H. ANDERSON LIVING TRUST
	
                 

              	
                 

              	
                 

              
	 	By:	/s/ Bonnie Anderson
	 		Bonnie Anderson, its Trustee

      

       

    (Castle Biosciences, Inc. Fifth Amended and Restated Investors’ Rights Agreement)

    
      
        
 

    

    
      	
               

            	INVESTOR:
	
               

            	
               

            	
               

            
	
               

            	DAVID L. MAHONEY AND WINNIFRED C. ELLIS 1998 FAMILY TRUST
	
               

            	
               

            	
               

            
	 	By:	/s/ David L. Mahoney
	 		David L. Mahoney, its Trustee

    

    

    

    (Castle Biosciences, Inc. Fifth Amended and Restated Investors’ Rights Agreement)

    
      
        
 

    

    
      	 	INVESTOR:
	 	 	 
	 	/s/ Daniel G. Crockett 
	 	Daniel G. Crockett

    

    

    

     (Castle Biosciences, Inc. Fifth Amended and Restated Investors’ Rights Agreement)

    
      
        
 

    

     
      
        	
                 

              	INVESTOR:
	
                 

              	
                 

              	
                 

              
	
                 

              	JUMBO SIGN LIMITED
	
                 

              	
                 

              	
                 

              
	 	By:	/s/ John Timothy Rucquoi Berger
	 	

              	John Timothy Rucquoi Berger,

                its Director

      

    

     

      (Castle Biosciences, Inc. Fifth Amended and Restated Investors’ Rights Agreement)

    
      
        
 

    

    

    
      	 	INVESTOR:
	 	 	 
	 	/s/ Vaughn D. Bryson 
	 	Vaughn D. Bryson

    

     

      (Castle Biosciences, Inc. Fifth Amended and Restated Investors’ Rights Agreement) 

    
      
        
 

    

     
      	
               

            	INVESTORS:
	
               

            	
               

            
	
               

            	
	
               

            	Joe Cook, Jr.
	
               

            	
	
               

            	
	
               

            	Jamie L. Dingley
	
               

            	
	
               

            	
	
               

            	Tobin W. Juvenal
	
               

            	
               

            
	 	
	
               

            	Susan Juvenal
	
               

            	
	
               

            	
	
               

            	Gregory J. Lausier
	
               

            	
	
               

            	
	
               

            	Derek J. Maetzold
	
               

            	
	
               

            	
	
               

            	Beth A. Smith
	
               

            	
	
               

            	
	
               

            	Byron W. Smith
	
               

            	
	
               

            	/s/ Thomas P. Sullivan
	
               

            	Thomas P. Sullivan
	 	 

    

    

      (Castle Biosciences, Inc. Fifth Amended and Restated Investors’ Rights Agreement) 

    

    
      
        
 

    

              

    

    
      	
               

            	INVESTORS:
	
               

            	
               

            
	
               

            	
	
               

            	Joe Cook, Jr.
	
               

            	
	
               

            	
	
               

            	Jamie L. Dingley
	
               

            	
	
               

            	
	
               

            	Tobin W. Juvenal
	
               

            	
	 	
	
               

            	Susan Juvenal
	
               

            	
	
               

            	
	
               

            	Gregory J. Lausier
	
               

            	
	
               

            	/s/ Derek
                J. Maetzold     
	
               

            	Derek J. Maetzold
	
               

            	
	
               

            	
	
               

            	Beth A. Smith
	
               

            	
	
               

            	
	
               

            	Byron W. Smith
	
               

            	
	
               

            	
	
               

            	Thomas P. Sullivan

       

    (Castle Biosciences, Inc. Fifth Amended and Restated Investors’ Rights Agreement) 

  

  
    
      
 

  

  
    	
             

          	INVESTORS:
	
             

          	
             

          
	
             

          	
	
             

          	Joe Cook, Jr.
	
             

          	
	
             

          	
	
             

          	Jamie L. Dingley
	
             

          	
	
             

          	/s/ Tobin W.
              Juvenal   
	
             

          	Tobin W. Juvenal
	
             

          	
	 	/s/ Susan
              Juvenal 
	
             

          	Susan Juvenal
	
             

          	
	
             

          	
	
             

          	Gregory J. Lausier
	
             

          	
	
             

          	
	
             

          	Derek J. Maetzold
	
             

          	
	
             

          	
	
             

          	Beth A. Smith
	
             

          	
	
             

          	
	
             

          	Byron W. Smith
	
             

          	
	
             

          	
	
             

          	Thomas P. Sullivan

    

      (Castle Biosciences, Inc. Fifth Amended and Restated Investors’ Rights Agreement) 

    
      
        
 

    

     
      
        	
                 

              	INVESTOR:
	
                 

              	
                 

              	
                 

              
	
                 

              	SUSAN MARY SEERY REVOCABLE TRUST
	
                 

              	
                 

              	
                 

              
	 	By:	/s/ Susan Mary Seery  
	 	
                Name: Susan Mary Seery

                Its: Trustee

              

      

    

    

    (Castle Biosciences, Inc. Fifth Amended and Restated Investors’ Rights Agreement) 

    
      
        
 

    

     
      	
               

            	INVESTORS:
	
               

            	
               

            
	
               

            	
	
               

            	Joe Cook, Jr.
	
               

            	
	
               

            	/s/ Jamie
                L. Dingley  
	
               

            	Jamie L. Dingley
	
               

            	
	
               

            	
	
               

            	
              Tobin W. Juvenal

            
	
               

            	
	 	
	
               

            	Susan Juvenal
	
               

            	
	
               

            	
	
               

            	Gregory J. Lausier
	
               

            	
	
               

            	
	
               

            	Derek J. Maetzold
	
               

            	
	
               

            	
	
               

            	Beth A. Smith
	
               

            	
	
               

            	
	
               

            	Byron W. Smith
	
               

            	
	
               

            	
	
               

            	Thomas P. Sullivan

    

    

    

    (Castle Biosciences, Inc. Fifth Amended and Restated Investors’ Rights Agreement) 

  

  
    
      
 

  

  
    	
             

          	INVESTORS:
	
             

          	
             

          
	
             

          	 
	
             

          	Joe Cook, Jr.
	 	 
	 	 
		Jamie L. Dingley
	 	 
	 	 
		Tobin W. Juvenal
	 	 
	 	 
		Susan Juvenal
	 	 
		/s/ Gregory
              J. Lausier  
		Gregory J. Lausier
	 	 
	 	 
		Derek J. Maetzold
	 	 
	 	 
		Beth A. Smith
	 	 
	 	 
		Byron W. Smith
	 	 
	 	 
	 	Thomas P. Sullivan

    

    

    (Castle Biosciences, Inc. Fifth Amended and Restated Investors’ Rights Agreement) 

    
      
        
 

    

    
      	
               

            	INVESTORS:
	
               

            	
               

            	
               

            
	
               

            	SPINDLE TOP HEALTHCARE CAPITAL. L.P.
	
               

            		
               

            
	 	By: Spindletop Capital GP, L.P., its general partner 
	 	By: Spindletop GP of Management, LLC, its general partner
	 	 	 
	 	By:	 /s/ Evan Melrose
	 	
              Name: Evan Melrose

              Title: Manager

            

    

     

    
      	
               

            	SPINDLE TOP HEALTHCARE INVESTORS II, LLC
	
               

            		
               

            
	 	By: Texas Health Capital Partners, LLC, its manager
	 	 	 
	 	By:	/s/ Evan Melrose
	 	
              Name: Evan Melrose

              Title: Manager

            

    

            

    

    (Castle Biosciences, Inc. Fifth Amended and Restated Investors’ Rights Agreement)

  
    
      
 

  

  
    
      
        	 	INVESTOR:
	 	 	 
	 	/s/ Bradford Whitmore 
	 	Bradford Whitmore

      

       

    (Castle Biosciences, Inc. Fifth Amended and Restated Investors’ Rights Agreement)

    
      
        
 

    

    
      	 	
              INVESTOR:

            
	 	 
	
               

            	GORE RANGE CAPITAL VENTURE 1 LLC
	 	 	 
		By:	/s/ Ethan Rigel
	 	
              Name: Ethan Rigel

              Title: Member of the Managing Member

            

    

    

    

    (Castle Biosciences, Inc. Fifth Amended and Restated Investors’ Rights Agreement)

    
      
        
 

    

    
      	 	
              INVESTOR:

            
	 	 
	
               

            	JATEM BLUE, LLC
	 	 	 
	 	By:	/s/ Edward Mullen  
	 	
              Name: Edward Mullen

              Title: Manager

            

    

    

    (Castle Biosciences, Inc. Fifth Amended and Restated Investors’ Rights Agreement)

  
    
      
 

  

  
    
      	 	INVESTOR:
	 	 	 
	 	/s/ Patrick M. Hall    
	 	Patrick M. Hall

    

    

      (Castle Biosciences, Inc. Fifth Amended and Restated Investors’ Rights Agreement)

    
      
        
 

    

    

    
      	 	INVESTOR:
	 	 	 
	 	/s/ Gregory P. Schafer    
	 	Gregory P. Schafer

    

    

    

    (Castle Biosciences, Inc. Fifth Amended and Restated Investors’ Rights Agreement)

    
      
        
 

    

    

    
      	 	
              INVESTOR:

            
	 	 
	
               

            	UBS FINANCIAL SERVICES CUSTODIAN FOR ALICE BAHNER IZZO
	 	 	 
	 	By:	 /s/ Nicole Felix  

            
	 	
              Name: Nicole Felix

              Title: Asst. Ops. Manager

            

    

    

      (Castle Biosciences, Inc. Fifth Amended and Restated Investors’ Rights Agreement)

    
      
        
 

    

    

      
        	 	INVESTOR:
	 	 	 
	 	/s/ E. Jeffrey Peierls        
	 	E. Jeffrey Peierls

      

    

    

      (Castle Biosciences, Inc. Fifth Amended and Restated Investors’ Rights Agreement)

    
      
        
 

    

    

      
        	 	
                INVESTOR:

              
	 	 
	
                 

              	THE PEIERLS FOUNDATION, INC.
	 	 	 
	 	By:	/s/ E. Jeffrey Peierls
	 	
                Name: E. Jeffrey Peierls

                Title: President

              

      

    

  

  

    (Castle Biosciences, Inc. Fifth Amended and Restated Investors’ Rights Agreement)

  
    
      
 

  

  

    
      	
               

            	INVESTORS:
	
               

            	
               

            	
               

            
	
               

            	UD E.S. PEIERLS FOR E.F. PEIERLS ET AL
	
               

            	
               

            	
               

            
	 	By:	/s/ Michael F. Burke 
	

            	
              Name: Michael F. Burke

              Title: Senior Vice President, Bank of America, N.A, Co-Trustee

            

    

    
      	
               

            	
               

            	
               

            
	
               

            	UW E.S. PEIERLS FOR BRIAN E. PEIERLS – ACCUMULATION
	
               

            	
               

            	
               

            
	 	By:	/s/ Michael F. Burke
	 	
              Name: Michael F. Burke

              Title: Senior Vice President, Bank of America, N.A, Co-Trustee

            

    

    
      	
               

            	
               

            	
               

            
	
               

            	UW E.S. PEIERLS FOR E. JEFFREY PEIERLS – ACCUMULATION
	
               

            	
               

            	
               

            
	 	By:	/s/ Michael F. Burke
	 	
              Name: Michael F. Burke

              Title: Senior Vice President, Bank of America, N.A, Co-Trustee

            

    

    

    

    (Castle Biosciences, Inc. Fifth Amended and Restated Investors’ Rights Agreement) 

    
      
        
 

    

    
      	 	INVESTOR:
	 	 	 
	 	/s/ Brian Eliot Peierls      
	 	
              Brian Eliot Peierls

            

    

  

  

  

  (Castle Biosciences, Inc. Fifth Amended and Restated Investors’ Rights Agreement) 

    
      
        
 

    

    

  

  

  

  
    	
             

          	INVESTORS:
	
             

          	
             

          	
             

          
	
             

          	
            UD E.F. PEIERLS FOR BRIAN E. PEIERLS

            

          
	 	 	 
	
             

          	
            By: 

          	
            /s/ Alexis L. Borrelli

          
	
             

          	
            Name: Alexis L. Borrelli

          
	 	Title: Officer, The Northern Trust Company of Delaware

  

  

  

  
    

    
      	
               

            	UD E.F. PEIERLS FOR E. JEFFREY PEIERLS
	 	 	 
	
               

            	
              By: 

            	
              /s/ Alexis L. Borrelli

            
	
               

            	
              Name: Alexis L. Borrelli

            
	 	Title: Officer, The Northern Trust Company of Delaware

    

    

    

    
      

      
        	
                 

              	UD J.N. PEIERLS FOR BRIAN ELIOT PEIERLS
	 	 	 
	
                 

              	
                By: 

              	
                /s/ Alexis L. Borrelli

              
	
                 

              	
                Name: Alexis L. Borrelli

              
	 	Title: Officer, The Northern Trust Company of Delaware

      

      
        

        

        
          

          
            	
                     

                  	UD J.N. PEIERLS FOR E. JEFFREY PEIERLS
	 	 	 
	
                     

                  	
                    By: 

                  	
                    /s/ Alexis L. Borrelli

                  
	
                     

                  	
                    Name: Alexis L. Borrelli

                  
	 	Title: Officer, The Northern Trust Company of Delaware

          

          

          

        

      

      (Castle Biosciences, Inc. Fifth Amended and Restated Investors’ Rights Agreement)

      
        
          
 

      

    

    
      

      
        	
                 

              	INVESTORS:
	 	 
	 	UW J.N. PEIERLS FOR BRIAN E PEIERLS
	 	 	 
	
                 

              	
                By: 

              	
                /s/ Alexis L. Borrelli

              
	
                 

              	
                Name: Alexis L. Borrelli

              
	 	Title: Officer, The Northern Trust Company of Delaware

      

      
        

        

        
          

          
            	
                     

                  	UW J.N. PEIERLS FOR E. JEFFREY PEIERLS
	 	 	 
	
                     

                  	
                    By: 

                  	
                    /s/ Alexis L. Borrelli

                  
	
                     

                  	
                    Name: Alexis L. Borrelli

                  
	 	Title: Officer, The Northern Trust Company of Delaware

          

          
            

            

            
              

              
                	
                         

                      	UD ETHEL F. PEIERLS CHARITABLE LEAD TRUST
	 	 	 
	
                         

                      	
                        By: 

                      	
                        /s/ Alexis L. Borrelli

                      
	
                         

                      	
                        Name: Alexis L. Borrelli

                      
	 	Title: Officer, The Northern Trust Company of Delaware

              

            

          

        

      

    

    
      

      

      
        

        
          	
                   

                	THE PIERELS BYPASS TRUST
	 	 	 
	
                   

                	
                  By: 

                	
                  /s/ Alexis L. Borrelli

                
	
                   

                	
                  Name: Alexis L. Borrelli

                
	 	Title: Officer, The Northern Trust Company of Delaware

        

      

    

    

    

    (Castle Biosciences, Inc. Fifth Amended and Restated Investors’ Rights Agreement)

    
      
        
 

    

  

  Counterpart Signature Page 

  To

  Fifth Amended and Restated Investors’ Rights Agreement,

  Fourth Amended and Restated Right of First Refusal and Co-Sale Agreement 

  And

  Third Amended and Restated Voting Agreement 

  

  

  January 12, 2018

  

  

  Reference is made to that certain Second Series F Preferred Stock and Warrant Purchase Agreement, dated as of January 12, 2018, by and among Castle Biosciences, Inc. and the persons and entities listed on the Schedule of Investors attached thereto as Exhibit A (the “Purchase Agreement”).  Capitalized

    terms used but not defined herein shall have the meanings assigned to them in the Purchase Agreement.

   

  In connection with the purchase by the undersigned of Shares under the Purchase Agreement, the undersigned hereby agrees to be bound by the
    terms and conditions of each of the: (i) Amended Rights Agreement, a copy of which is attached hereto as Exhibit A (the “Rights Agreement”); (ii) ROFR/Co-Sale Agreement, a copy of which is attached hereto as Exhibit B (the “Co-Sale Agreement”); and (iii) Voting Agreement, a copy of which is attached hereto as Exhibit C (the “Voting Agreement”).

   

  Upon the execution of this counterpart signature page and the purchase of the Shares by the undersigned, the undersigned shall become: (i)
    an “Investor” and a party for all purposes under the Rights Agreement; (ii) a “Preferred Holder” and/or a “Common Holder,” as applicable, and a party for all
      purposes under the Co-Sale agreement; and (iii) a “Preferred Holder” and a party for all purposes under the Voting Agreement.

   

  [Signature Page Follows]

  
    
      
 

  

  IN WITNESS WHEREOF, the undersigned has executed this Counterpart Signature Page as of the date set forth above.

   

  
    	
             

          	
            /s/ Joseph C. Cook III

          
	
             

          	
            Cook, Joseph C., III

          

  

  
    
      
 

  

  IN WITNESS WHEREOF, the undersigned has executed this Counterpart Signature Page as of the date set forth above.

   

  
    

    
      	
               

            	
              /s/ Steven D. Singleton

            
	
               

            	
              Singleton, Steven D.

            

    

  

  

  
    
      
 

  

  IN WITNESS WHEREOF, the undersigned has executed this Counterpart Signature Page as of the date set forth above.

   

  
    

    
      

      
        	 	
                The Abigail A. Smith Gift Trust u/a/d

                November 29, 2007

              
	 	 
	
                 

              	
                /s/ Paul Douglas Wilson

              
	
                 

              	
                Paul Douglas Wilson, Trustee

              

      

    

  

  
    

    
      

      

    

  

   
  
    
      
 

  

  IN WITNESS WHEREOF, the undersigned has executed this Counterpart Signature Page as of the date set forth above.

   
    

    
      

      
        

        
          	 	
                  The Andrew A. Smith Gift Trust u/a/d

                  November 29, 2007

                
	 	 
	
                   

                	
                  /s/ Paul Douglas Wilson

                
	
                   

                	
                  Paul Douglas Wilson, Trustee

                

        

      

    

    
      

      

      
        
          
 

      

    

  

  IN WITNESS WHEREOF, the undersigned has executed this Counterpart Signature Page as of the date set forth above.

   

  
    

    
      

      
        

        
          	 	
                  The Colin W. Smith Gift Trust u/a/d

                  November 29, 2007

                
	 	 
	
                   

                	
                  /s/ Paul Douglas Wilson

                
	
                   

                	
                  Paul Douglas Wilson, Trustee

                

        

      

    

  

   
  
    
      
 

  

  IN WITNESS WHEREOF, the undersigned has executed this Counterpart Signature Page as of the date set forth above.

   

  
    

    
      

      
        

        
          

          
            	
                     

                  	
                    /s/ Jamie L. Dingley

                  
	
                     

                  	
                    Jamie L. Dingley

                  

          

        

      

    

     

  
    
      
 

  

  IN WITNESS WHEREOF, the undersigned has executed this Counterpart Signature Page as of the date set forth above.

   

  
    

    
      

      
        

        
          

          
            

            
              	
                       

                    	
                      /s/ John Abbot

                    
	
                       

                    	
                      John Abbot for Rachel Abbott

                    

            

          

        

      

    

  

   

  
    
      
 

  

  IN WITNESS WHEREOF, the undersigned has executed this Counterpart Signature Page as of the date set forth above.

   

  
    

    
      

      
        

        
          

          
            

            
              

              
                	
                         

                      	
                        /s/ Bernhard E. Spiess

                      
	
                         

                      	
                        Bernhard E. Spiess

                      

              

            

          

        

      

    

     

    
      
        
 

    

  

  IN WITNESS WHEREOF, the undersigned has executed this Counterpart Signature Page as of the date set forth above.

   
    

    
      

      
        

        
          

          
            

            
              

              
                

                
                  	
                           

                        	
                          /s/ Clare Johnson

                        
	
                           

                        	
                          Clare Johnson

                        

                

              

            

          

        

      

       

      
        
          
 

      

    

  

  

  IN WITNESS WHEREOF, the undersigned has executed this Counterpart Signature Page as of the date set forth above.

   

  
    

    
      

      
        

        
          

          
            

            
              

              
                

                
                  	
                           

                        	
                          /s/ Trisha Poteet

                        
	
                           

                        	
                          Trisha Poteet

                        

                

              

            

          

        

      

       

    

  

  

  
    
      
 

  

  IN WITNESS WHEREOF, the undersigned has executed this Counterpart Signature Page as of the date set forth above.

   
    

    
      

      
        

        
          

          
            

            
              

              
                

                
                  

                  
                    	
                             

                          	
                            /s/ James D. Baxter

                          
	
                             

                          	
                            James D. Baxter

                          

                  

                

              

            

          

        

        

        
          
            
 

        

      

    

  

  IN WITNESS WHEREOF, the undersigned has executed this Counterpart Signature Page as of the date set forth above.

   
    

    
      

      
        

        
          

          
            

            
              

              
                

                
                  

                  
                    	
                             

                          	
                            /s/ Mara G. Aspinall

                          
	
                             

                          	
                            Mara G. Aspinall

                          

                  

                

              

            

          

        

        

        
          
            
 

        

      

    

  

  IN WITNESS WHEREOF, the undersigned has executed this Counterpart Signature Page as of the date set forth above.

   

  
    

    
      

      
        

        
          

          
            

            
              

              
                

                
                  

                  
                    	
                             

                          	
                            /s/ John W. Abbott

                          
	
                             

                          	
                            John W. Abbott

                          

                  

                

              

            

          

        

      

    

  

  
    
      
 

  

  IN WITNESS WHEREOF, the undersigned has executed this Counterpart Signature Page as of the date set forth above.

   

  
    

    
      

      
        

        
          

          
            

            
              

              
                

                
                  

                  
                    

                    
                      	
                               

                            	
                              /s/ Tyler Whitmore

                            
	
                               

                            	
                              Tyler Whitmore

                            

                    

                  

                

              

            

          

        

      

    

  

   

  
    
      
 

  

  IN WITNESS WHEREOF, the undersigned has executed this Counterpart Signature Page as of the date set forth above.

   
    

    
      

      
        

        
          

          
            

            
              

              
                

                
                  

                  
                    

                    
                      

                      
                        	
                                 

                              	
                                /s/ Chancie Hall

                              
	
                                 

                              	
                                Chancie Hall

                              

                      

                    

                  

                

              

            

          

        

      

    

     

    
      
        
 

    

  

  IN WITNESS WHEREOF, the undersigned has executed this Counterpart Signature Page as of the date set forth above.

   
    

    
      

      
        

        
          

          
            

            
              

              
                

                
                  

                  
                    

                    
                      

                      
                        	
                                 

                              	
                                /s/ Matt Falk

                              
	
                                 

                              	
                                Matt Falk

                              

                      

                    

                  

                

              

            

          

        

      

    

  

  

  

  
    
      
 

  

  IN WITNESS WHEREOF, the undersigned has executed this Counterpart Signature Page as of the date set forth above.

   
    
      

      
        

        
          

          
            

            
              

              
                

                
                  

                  
                    

                    
                      

                      
                        

                        
                          	
                                   

                                	
                                  /s/ Chris L. Otte

                                
	
                                   

                                	
                                  Chris L. Otte

                                

                        

                      

                    

                  

                

              

            

          

        

      

    

              

    
      
        
 

    

    

  

  EXHIBIT A

   

  INVESTORS

   

  
    	
            Industry Ventures Healthcare, LLC

          	
            with a copy to:

          
	
            30 Hotaling Place, Ste. 300

          	
            Ryan D. Thomas

          
	
            San Francisco, CA 94111

          	
            Bass, Berry & Sims PLC

          
	
            Attn: Victor Hwang

          	
            150 Third Avenue South

          
	 	
            Suite 2800

          
	 	
            Nashville, TN 37201

          
	 	 
	
            Sofinnova HealthQuest Partners, L.P.

          	
            with a copy to:

          
	
            3000 Sand Hill Road, Bldg. 4, Ste. 250

          	
            Ryan D. Thomas

          
	
            Menlo Park, CA 94025

          	
            Bass, Berry & Sims PLC

          
	
            Attn: Garheng Kong and Hooman

          	
            150 Third Avenue South

          
	
            Shahlavi

          	
            Suite 2800

          
	 	
            Nashville, TN 37201

          
	 	 
	
            MGC Venture Partners 2013, L.P.

          	
            with a copy to:

          
	
            3835 Cleghorn Ave., Ste. 300

          	
            Robert Laird

          
	
            Nashville, TN 37215

          	
            McKenzie Laird PLLC

          
	 	
            3835 Cleghorn Ave., Ste. 250

          
	 	
            Nashville, TN 37215

          
	 	 
	
            BioBrit, LLC

          	 
	
            5462 Soledad Road

          	 
	
            La Jolla, CA 92037

          	 
	 	 
	
            Steven D. Singleton

          	 
	 	 
	
            Spindletop Healthcare Capital, L.P.

          	 
	
            3571 Far West Blvd., PMB 108

          	 
	
            Austin, Texas 78731

          	 
	
            Attn: Evan Melrose

          	 
	 	 
	
            Spindletop Healthcare Investors II, LLC

          	 
	
            3571 Far West Blvd., PMB 108

          	 
	
            Austin, Texas 78731

          	 
	
            Attn: Evan Melrose

          	 

    

    

    
      
        
 

    

    

  

   

  Joseph C. Cook, III

  

  

  Longfellow Venture Partners I, LLC

  P.O. Box 380199

  Cambridge, MA 02238

  

  

  Kolterman Family Trust

  

  

  Byron W. Smith

  

  

  Farview Management Co. L.P.

  3835 Cleghorn Ave., Ste. 300

  Nashville, TN 37215

  

  

  Derek J. Maetzold

  

  

  Joe Cook, Jr.

  

  

  Jumbo Sign Limited

  Post Office Box 23291

  Wanchai Post Office

  Hong Kong

  Attn: John Timothy Rucquoi Berger 

  
    
      
 

  

  Alma Life Sciences, LLC

  8540 Avenida De Las Ondas

  La Jolla, CA 92037

  Attn: Francois Ferre

  

  

  Vaughn D. Bryson

  

  

  Daniel G. Crockett

  c/o Todd Glisson

  Covenant Partners, LLC

  P.O. Box 158187

  Nashville, TN 37215

  

  

  David L. Mahoney and Winnifred C. Ellis 1998 Family Trust

  Attn: David L. Mahoney

  

  

  James and Pamela Wilson Trust

  

  

  Wilson Family Partners

  

  

  Tobin W. Juvenal and Susan Juvenal

  

  

  Andy Sassine 

  
    
      
 

  

  Bonnie H. Anderson Living Trust

  

  

  Jamie L. Dingley

  

  

  Gregory J. Lausier

  

  

  Beth A. Smith

  

  

  John B. Juvenal and Leanne Juvenal Revocable Trust

  

  

  Susan Mary Seery Revocable Trust

  

  

  Thomas P. Sullivan

  

  

  Pelmea Limited Partnership

  P.O. Box 380199

  Cambridge, MA 02238

  

  

  Pensco Trust Company LLC

  Custodian for Alice Bahner Izzo

  Pensco Trust Company LLC

  P. O. Box 173859

  Denver, CO 80217

  
    
      
 

  

  

  Patrick M. Hall

  

  

  Gregory P. Schafer

  

  

  Gore Range Capital Venture 1 LLC

  2121 N. Frontage Rd. West #253

  Vail, CO 81657

  Attn: Ethan Rigel

  

  

  JATEM Blue, LLC

  8895 N. Military Trail, Suite B301

  Palm Beach Gardens, FL 33410

  Attn: Edward Mullen

  

  

  E. Jeffrey Peierls

  

  

  Brian Eliot Peierls

  

  

  UD E.F. Peierls for Brian E. Peierls

  c/o The Northern Trust Company of

  Delaware 1313 N. Market Street, Suite 5300

  Wilmington, DE 19801

  Attn: Alexis Borrelli

  

  
    
      
 

  

  UD E.F. Peierls for E. Jeffrey Peierls

  c/o The Northern Trust Company of Delaware

  1313 N. Market Street, Suite 5300

  Wilmington, DE 19801

  Attn: Alexis Borrelli

  

  

  UD J.N. Peierls for Brian Eliot Peierls

  c/o The Northern Trust Company of Delaware

  1313 N. Market Street, Suite 5300

  Wilmington, DE 19801

  Attn: Alexis Borrelli

  

  

  UD J.N. Peierls for E. Jeffrey Peierls

  c/o The Northern Trust Company of Delaware

  1313 N. Market Street, Suite 5300

  Wilmington, DE 19801

  

  

  UW J.N. Peierls for Brian E. Peierls

  c/o The Northern Trust Company of Delaware

  1313 N. Market Street, Suite 5300

  Wilmington, DE 19801

  

  

  UW J.N. Peierls for E. Jeffrey Peierls

  c/o The Northern Trust Company of Delaware

  1313 N. Market Street, Suite 5300

  Wilmington, DE 19801

  

  

  UD Ethel F. Peierls Charitable Lead Trust

  c/o The Northern Trust Company of Delaware

  1313 N. Market Street, Suite 5300

  Wilmington, DE 19801

  
    
      
 

  

  The Peierls Bypass Trust

  c/o The Northern Trust Company of Delaware

  1313 N. Market Street, Suite 5300

  Wilmington, DE 19801

  Attn: Alexis Borrelli

  

  

  The Peierls Foundation, Inc.

  

  

  UD E.S. Peierls for E.F. Peierls et al

  

  

  UW E.S. Peierls for Brian E. Peierls –

  Accumulation

  

  

  UW E.S. Peierls for E. Jeffrey Peierls –

  Accumulation

  

  

  The Colin W. Smith Gift Trust

  u/a/d November 29, 2007

  

  
    
      
 

  

  The Abigail A. Smith Gift Trust u/a/d November 29, 2007

  

  

  The Andrew A. Smith Gift Trust u/a/d November 29, 2007

  

  

  Mara G. Aspinall

  

  

  James Braxton

  

  

  Trisha Poteet

  

  

  Clare Johnson

  

  

  Bernhard Spiess

  

  

  Bahner Izzo Family Trust

  Paul Izzo and Alice Bahner Izzo, Trustees

  c/o Julie Pitpit

  UBS Financial Services Inc.

  1200 Prospect Street, Suite 500

  La Jolla, CA 92037

  
    
      
 

  

  Chris Otte

  

  

  John Abbott

  

  

  Matt Falk

  

  

  Chancie Hall

  

  

  Tyler Whitmore

  

  

  Jack Abbott

  

  

  Carol Shumate

  

  

  Jan Matchus

  

  

  Mike Abbott

  
    
      
 

  

  SCHEDULE 1

   

  NOTICE AND WAIVER/ELECTION OF

    RIGHT OF FIRST REFUSAL

   

  I do hereby waive or exercise, as indicated below, my rights of first refusal under the Fifth Amended and Restated
    Investors’ Rights Agreement dated as of July 15, 2015 (the “Agreement”):

   

  1.          Waiver of twenty (20) days’ notice period in which
      to exercise right of first refusal: (please check only one)

   

  
    		(  )	
            WAIVE in full, on behalf of all Holders, the twenty (20) day notice
              period provided to exercise my right of first refusal granted under the Agreement.

          

  

   

  
    		(  )	
            DO NOT WAIVE the notice period described above.

          

  

   

  2.          Issuance and Sale of New Securities: (please check only one)

   

  
    		(  )	
            WAIVE in full the right of first refusal granted under the
              Agreement with respect to the issuance of the New Securities.

          

  

   

  
    		(  )	
            ELECT TO PARTICIPATE in $_________ (please provide amount) in New Securities proposed to be issued by Castle Biosciences, Inc., a Delaware corporation, representing LESS than my pro rata portion of the
              aggregate of $[____________] in New Securities being offered in the financing.

          

  

   

  
    		(  )	
            ELECT TO PARTICIPATE in $_________ in New Securities proposed to be
              issued by Castle Biosciences, Inc., a Delaware corporation, representing my FULL pro rata portion of the aggregate of $[____________] in
              New Securities being offered in the financing.

          

  

   

  
    		(  )	
            ELECT TO PARTICIPATE in my full pro rata portion of the aggregate of $[____________] in New Securities being made available in the financing AND, to the extent available, the greater of (x) an
              additional $_________ (please provide amount) or (y) my pro rata portion of any remaining investment amount available in the event other Significant Holders do not exercise their full rights of first refusal with respect to the $[____________] in New Securities being
              offered in the financing.

          

  

   

  
    	
            Date:________________________________

            

          	 
	 	
            (Print investor name)

          
	 	 
	 	 
	 	
            (Signature)

          
	 	 
	 	 
	 	
            (Print name of signatory, if
                signing for an entity)

          
	 	 
	 	 
	 	
            (Print title of signatory,
                if signing for an entity)

          

    

    

    
    This is neither a commitment to purchase nor a commitment to issue the New Securities described
        above. Such issuance can only be made by way of definitive documentation related to such issuance. The company will supply you with such definitive documentation upon request or if you indicate that you would like to exercise your first offer
        rights in whole or in part. 

    
      
        
 

    

     

  

  
    

    

    FIRST AMENDMENT TO

    FIFTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT

    

    

    This First Amendment (this “Amendment”) to that certain Fifth Amended and Restated Investors’ Rights Agreement, dated as of July 15, 2015 (the “Agreement”),

      by and among Castle
          Biosciences, Inc., a Delaware corporation (the “Company”), and the persons and entities listed on Exhibit A thereto (each, an “Investor” and collectively, the “Investors”), is made and entered into as of
      January 12, 2018 by and among the Company and the Investors listed on the signature pages hereto. Capitalized terms used and not otherwise defined herein shall have the respective meanings given to them in the Agreement.

    

    

    WHEREAS, the Company and the
      Investors entered into the Agreement, which provides for certain registration rights, information rights and rights of first refusal, among others;

    

    

    WHEREAS, Section 7.1 of the
      Agreement provides that the Agreement may be amended by the written consent the Company and the Holders holding a majority of the Registrable Securities (excluding any of such shares that have been sold to the public or pursuant to Rule 144) and each
      of the Major Investors (the “Requisite Investors”); and

    

    

    WHEREAS, the undersigned constitute
      the Company and the Requisite Investors.

    

    

    NOW, THEREFORE, in accordance with
      the foregoing and intending to be legally bound hereby, the parties hereto agree to amend the Agreement as follows:

    

    

    1.           Section 2.12 of the
        Agreement is hereby amended and restated in its entirety to read as follows:

    

    

    “2.12         

      Transfer or Assignment of Registration Rights. The rights to cause the
        Company to register securities granted to a Holder by the Company under this Section 2 may be transferred or assigned by a Holder only to a transferee or assignee that is: (a) an affiliate of a Holder; (b) another Holder; (c) a Holder’s immediate
        family member or trust for the benefit of an individual Holder or one or more of such Holder’s immediate family members; or (d) the transferee or assignee of not less than 10,000 shares of Registrable Securities (as presently constituted and
        subject to subsequent adjustments for stock splits, stock dividends, reverse stock splits, and the like); provided that (i) such transfer or
        assignment of Registrable Securities is effected in accordance with the terms of Section 2.8 and applicable securities laws, (ii) the Company is given written notice prior to said transfer or assignment, stating the name and address of the
        transferee or assignee and identifying the securities with respect to which such registration rights are intended to be transferred or assigned and (iii) the transferee or assignee of such rights assumes in writing the obligations of such Holder
        under this Agreement, including without limitation the obligations set forth in Section 2.10.”

     

    

    

    2.           The opening paragraph of
        Section 4.1 of the Agreement is hereby amended and restated in its entirety to read as follows:

    
      1

      
        
 

    

    
    “4.1           Right of First Refusal to
        Significant Holders. The Company hereby grants to each Holder who owns at least 10,000 Shares or Conversion Stock (as presently constituted and subject to subsequent adjustments for stock splits, stock dividends, reverse stock splits and the
      like) (the “Significant Holders”), the right of first refusal to purchase its pro rata share of New Securities (as defined in this Section 4.1(a)) which the Company may, from time to time, propose to sell and issue after the date of this Agreement. A
      Significant Holder’s pro rata share, for purposes of this right of first refusal, is equal to the ratio of (a) the number of shares of Preferred Stock owned by such Significant Holder immediately prior to the issuance of New Securities (assuming full
      conversion or exercise of all outstanding convertible securities, rights, options and warrants for Preferred Stock held by said Significant Holder) to (b) the total number of shares of Preferred Stock outstanding immediately prior to the issuance of
      New Securities (assuming full conversion or exercise of all outstanding convertible securities, rights, options and warrants for Preferred Stock). Each Significant Holder shall have a right of over-allotment such that if any Significant Holder fails
      to exercise its right hereunder to purchase its pro rata share of New Securities, the other Significant Holders may purchase the non-purchasing Significant Holder’s portion on a pro rata basis. This right of first refusal shall be subject to the
      following provisions:”

    

    

    3.           Section 4.1(a)(i) of the
        Agreement is hereby amended and restated in its entirety to read as follows:

    

    

    “(i)             the Conversion Stock
        and the Series F Preferred Stock issued and sold pursuant to Section 2.2 of the Purchase Agreement, as amended from time to time, and the Conversion Stock to be issued and sold pursuant to that certain Second Series F Preferred Stock and Warrant
        Purchase Agreement dated as of January 12, 2018 (the “Second Purchase Agreement”), including any such shares issued pursuant
        to the exercise of Series F Warrants (as defined in the Second Purchase Agreement);”

    

    

    4.           Section 4.2 of the
        Agreement is hereby amended and restated in its entirety to read as follows:

    

    

    “4.2          
      Assignment of Rights/Termination of Covenants. Each Significant Holder
        shall be entitled to assign its rights under this Section 4 to: (i) any affiliate of such Holder, (ii) any immediate family member of such Holder, and (iii) any trust for the benefit of such Holder or one or more of such Holder’s immediate family
        members. The covenants set forth in this Section 4 shall terminate upon and be of no further force and effect after the earliest to occur of: (a) the closing of the Company’s Initial Public Offering and (b) the consummation of a Liquidation Event
        or Deemed Liquidation Event.

    

    

    5.           Clause (i) of Section 5.3
        of the Agreement is hereby amended and restated in its entirety to read as follows:

    

    

    “(i)             make any capital
        expenditure in excess of $150,000 (individually, or in the aggregate, for a series of related capital expenditures);”

    

    

    6.           A new Section 7.13 shall be
        inserted following Section 7.12 of the Agreement, which shall read as follows:

    
      2

      
        
 

    

    
    “7.13.        Additional Investors. Notwithstanding anything to the contrary contained herein, any purchaser of Series F Preferred Stock pursuant to the Purchase Agreement, as amended from time to time, or pursuant to the Second
        Purchase Agreement may become a party to this Agreement by executing and delivering a counterpart signature page to this Agreement and shall be deemed an “Investor” and a party hereunder, without the need for an amendment of any of this Agreement
        except to add each such purchaser’s name to Exhibit A hereto, and such purchaser shall thereafter have the rights and obligations hereunder.”

    

    

    7.           Clause (c) of Section 7.2
        of the Agreement is hereby amended and restated in its entirety to read as follows:

    

    

     “(c) if to the Company, to the attention of the Chief Executive Officer of the Company at2014 San Miguel Drive, Friendswood, Texas
      77546, or at such other address as the Company shall have furnished to the Holders, with a copy to Karen Deschaine, Cooley LLP, 4401 Eastgate Mall, San Diego, CA 92121.”

    

    

    8.          Except as amended hereby, the
        Agreement shall remain in full force and effect and all of the rights and obligations under the Agreement are affirmed. In the event of a conflict between this Amendment and the Agreement, this Amendment shall control.

    

    

    9.           This Amendment shall be
        governed, construed and interpreted in accordance with the laws of the State of Delaware, without giving effect to principles of conflicts of laws.

    

    

    10.         This Amendment may be
        executed in any number of counterparts, each of which when executed will be deemed an original and all of which, taken together, will be deemed to be one and the same instrument. Any signature page delivered by facsimile or other electronic (i.e.,
        PDF) transmission shall be binding to the same extent as an original signature page.

    

    

    [Signature Pages Follow]

    
      3

      
        
 

    

    IN WITNESS WHEREOF, the Company and
      the Requisite Investors have executed this Amendment as of the date first set forth above.

    

    

    
      	
               

            	COMPANY:
	 	 
	 	CASTLE BIOSCIENCES, INC.
	 	a Delaware corporation
	
               

            	
               

            	
               

            
	
               

            	By:	/s/ Derek Maetzold
	
               

            	
               

            	Derek Maetzold
	
               

            	
               

            	President and Chief Executive Officer

    

    

    

    [Signature Page to First Amendment to Fifth Amended and Restated Investors’ Rights Agreement]

    
      
        
 

    

    
      	
               

            	INVESTOR:
	
               

            	
               

            	
               

            
	
               

            	BioBrit, LLC
	
               

            	
               

            	
               

            
	
               

            	By:	/s/ Daniel M. Bradbury
	 	
              Name: Daniel M. Bradbury

              Title: Managing Member 

            

    

     

    [Signature Page to First Amendment to Fifth Amended and Restated Investors’ Rights Agreement]

    
      
        
 

    

    
      	
               

            	INVESTOR:
	
               

            	
               

            	
               

            
	
               

            	Sofinnova HealthQuest Partners, L.P.
	
               

            	
               

            	
               

            
	
               

            	
              By:

            	/s/ Garheng Kong
	 	
              Name: Garheng Kong

              Title: Managing Member of HealthQuest Venture Management, L.L.C., the general partner of Sofinnova HealthQuest Partners, L.P.

            

    

    

    

    
      [Signature Page to First Amendment to Fifth Amended and Restated Investors’ Rights Agreement]

      
        
          
 

      

    

    	
             

          	INVESTOR:
	
             

          	
             

          	
             

          
	
             

          	Industry Ventures Healthcare, LLC
	
             

          	
             

          	
             

          
	
             

          	By: Industry Ventures Management VII, LLC,

            its General Partner
	
             

          	
             

          	
             

          
	 	By:	/s/ Victor Hwang
	 	
            Name: Victor Hwang

              Title: Member

          

    

    

    
      [Signature Page to First Amendment to Fifth Amended and Restated Investors’ Rights Agreement]

      
        
          
 

      

    

    	
             

          	INVESTOR:
	
             

          	
             

          	
             

          
	
             

          	MGC Venture Partners 2013, L.P.
	
             

          	
             

          	
             

          
	
             

          	By: MCC Venture Partners 2013 GP, LLC

            Its: General Partner
	
             

          	
             

          	
             

          
	 	By:	/s/ Joe Cook, III,
	 	Name: Joe Cook, III, Managing Member

               

    

    

    [Signature Page to First Amendment to Fifth Amended and Restated Investors’ Rights Agreement]

    
      
        
 

    

    	
             

          	INVESTOR:
	
             

          	
             

          
	
             

          	Joseph C. Cook Jr.
	
             

          	
             

          
	
             

          	/s/ Joseph C. Cook Jr.

    

    

    
      [Signature Page to First Amendment to Fifth Amended and Restated Investors’ Rights Agreement]

      
        
          
 

      

      	
               

            	INVESTOR:
	
               

            	
               

            
	
               

            	Joseph C. Cook III
	
               

            	
               

            
	
               

            	/s/ Joseph C. Cook III

      

      

      
        [Signature Page to First Amendment to Fifth Amended and Restated Investors’ Rights Agreement]

        
          
            
 

        

        	
                 

              	INVESTOR:
	
                 

              	
                 

              
	
                 

              	Steven D. Singleton
	
                 

              	
                 

              
	
                 

              	
                /s/ Steven D. Singleton

              

        

        

        
          [Signature Page to First Amendment to Fifth Amended and Restated Investors’ Rights Agreement]

          
            
              
 

          

        

        
          	
                   

                	INVESTOR:
	
                   

                	
                   

                	
                   

                
	
                   

                	The Abigail A. Smith Gift Trust u/a/d November 29, 2007
	
                   

                	
                   

                	
                   

                
	
                   

                	By:	/s/ Paul Douglas Wilson
	
                   

                	
                  Name: Paul Douglas Wilson

                    Title: Trustee

                

        

        

        [Signature Page to First Amendment to Fifth Amended and Restated Investors’ Rights Agreement]

        
          
            
 

        

        
          	
                   

                	INVESTOR:
	
                   

                	
                   

                	
                   

                
	
                   

                	The Andrew A. Smith Gift Trust u/a/d
	
                   

                	November 29, 2007
	
                   

                	
                   

                	
                   

                
	 	By:	/s/ Paul Douglas Wilson
	 	
                  Name: Paul Douglas Wilson

                  Title: Trustee

                

        

      

    

    

    

    
      [Signature Page to First Amendment to Fifth Amended and Restated Investors’ Rights Agreement]

      
        
          
 

      

    

    
      	
               

            	INVESTOR:
	
               

            	
               

            	
               

            
	
               

            	The Colin W. Smith Gift Trust u/a/d November 29, 2007
	
               

            	
               

            	
               

            
	
               

            	By:	/s/ Paul Douglas Wilson
	
               

            	
              Name: Paul Douglas Wilson

              Title: Trustee

            

    

    

    

    
      [Signature Page to First Amendment to Fifth Amended and Restated Investors’ Rights Agreement]

      
        
          
 

      

    

    
      	
               

            	INVESTOR:
	
               

            	
               

            	
               

            
	
               

            	Bradford Todd Whitmore
	
               

            	
               

            	
               

            
	
               

            	/s/ Bradford Todd Whitmore

    

    

    

    
      [Signature Page to First Amendment to Fifth Amended and Restated Investors’ Rights Agreement]

      
        
          
 

      

    

    
      	
               

            	INVESTOR:
	
               

            	
               

            	
               

            
	
               

            	Daniel G. Crockett
	
               

            	
               

            	
               

            
	
               

            	/s/ Daniel G. Crockett

    

    

    

    
      [Signature Page to First Amendment to Fifth Amended and Restated Investors’ Rights Agreement]

      
        
          
 

      

    

    
      	
               

            	INVESTOR:
	
               

            	
               

            	
               

            
	
               

            	David L. Mahoney for David L. Mahoney and Winnifred C. Ellis 1998 Family Trust
	
               

            	
               

            	
               

            
	
               

            	By:	/s/ David L. Mahoney
	
               

            	
              Name: David L. Mahoney

              Title: Trustee

            

    

    

    

    
      [Signature Page to First Amendment to Fifth Amended and Restated Investors’ Rights Agreement]

      
        
          
 

      

    

    
      	
               

            	INVESTOR:
	
               

            	
               

            	
               

            
	
               

            	Jumbo Sign Limited
	
               

            	
               

            	
               

            
	
               

            	By:	/s/ Rucquoi Berger
	
               

            	
              Name: Rucquoi Berger

              Title: Managing Director

            

    

    

    

    
      [Signature Page to First Amendment to Fifth Amended and Restated Investors’ Rights Agreement]

      
        
          
 

      

    

    
      	
               

            	INVESTOR:
	
               

            	
               

            	
               

            
	
               

            	Vaughn D. Bryson
	
               

            	
               

            	
               

            
	
               

            	/s/ Vaughn D. Bryson

    

    

    

    
      [Signature Page to First Amendment to Fifth Amended and Restated Investors’ Rights Agreement]

      
        
          
 

      

    

    
      	
               

            	INVESTOR:
	
               

            	
               

            
	
               

            	Thomas P. Sullivan
	
               

            	
               

            
	
               

            	/s/ Thomas P. Sullivan

    

    

    

    
      [Signature Page to First Amendment to Fifth Amended and Restated Investors’ Rights Agreement]

      
        
          
 

      

    

    
      	
               

            	INVESTOR:
	
               

            	
               

            	
               

            
	
               

            	Derek Maetzold
	
               

            	
               

            	
               

            
	
               

            	
              By:

            	
              /s/ Derek Maetzold

            
	
               

            	
              Name: Derek Maetzold

              Title: President, CEO, Board Member

            

    

    

    

    
      [Signature Page to First Amendment to Fifth Amended and Restated Investors’ Rights Agreement]

      
        
          
 

      

    

    
      	
               

            	INVESTOR:
	
               

            	
               

            	
               

            
	
               

            	
              Spindletop Healthcare Capital, L.P.

                Spindletop Healthcare Investors II, LLC

            
	
               

            	
               

            	
               

            
	
               

            	By:	/s/ Evan Melrose
	
               

            	
              Name: Evan Melrose

              Title: Managing Director

            

    

    

    

    
      [Signature Page to First Amendment to Fifth Amended and Restated Investors’ Rights Agreement]

      
        
          
 

      

    

    
      	
               

            	INVESTOR:
	
               

            	
               

            	
               

            
	
               

            	JATEM Blue, LLC
	
               

            	
               

            	
               

            
	
               

            	By:	/s/ Edward Mullen
	
               

            	
              Name: Edward Mullen

              Title: Manager

            

    

    
      

      

      [Signature Page to First Amendment to Fifth Amended and Restated Investors’ Rights Agreement]

      
        
          
 

      

    

    	
             

          	INVESTOR:
	
             

          	
             

          
	
             

          	/s/ Alice B. Izzo/ Paul P. Izzo
	
             

          	Bahner Izzo Family Trust

    

    

    
      [Signature Page to First Amendment to Fifth Amended and Restated Investors’ Rights Agreement]

      
        
          
 

      

    

    
      	
               

            	INVESTOR:
	
               

            	
               

            	
               

            
	
               

            	Jamie L. Dingley
	
               

            	
               

            	
               

            
	
               

            	/s/ Jamie L. Dingley

    

    

    

    
      [Signature Page to First Amendment to Fifth Amended and Restated Investors’ Rights Agreement]

      
        
          
 

      

    

    
      	
               

            	INVESTOR:
	
               

            	
               

            	
               

            
	
               

            	
              E. Jeffrey Peierls

              The Peierls Foundation, Inc. 

            
	
               

            	
               

            	
               

            
	
               

            	By:	/s/ E. Jeffrey Peierls
	
               

            	
              Name: E. Jeffrey Peierls

              Title: President of the Foundation

            

    

    

    

    
      [Signature Page to First Amendment to Fifth Amended and Restated Investors’ Rights Agreement]

      
        
          
 

      

    

    
      	
               

            	INVESTOR:
	
               

            	
               

            	
               

            
	
               

            	
              UD E.F. Peierls for Brian E. Peierls

              UD E.F. Peierls for E. Jeffrey Peierls

              UD J.N. Peierls for Brian Eliot Peierls

              UD J.N. Peierls for E. Jeffrey Peierls

              UW J.N. Peierls for Brian E. Peierls

              UW J.N. Peierls for E. Jeffrey Peierls

              UD Ethel F. Peierls Charitable Lead Trust

              The Peierls Bypass Trust

              UD E.S. Peierls for E.F. Peierls et al

              UW E.S. Peierls for Brian E. Peierls –Accumulation

              UW E.S. Peierls for E. Jeffrey Peierls–Accumulation

            
	
               

            	
               

            	
               

            
	
               

            	By: 	/s/ Deserae B. Smith 
	
               

            	
              Name: Deserae B. Smith

              Title: Vice President, On behalf of The Northern Trust Company of Delaware as Trustee

            

    

    

    

    
      [Signature Page to First Amendment to Fifth Amended and Restated Investors’ Rights Agreement]

      
        
          
 

      

    

    
      	
               

            	INVESTOR:
	
               

            	
               

            
	
               

            	Brian Eliot Peierls
	
               

            	
               

            
	
               

            	
              /s/ Brian Eliot Peierls

            

    

    

    

    
      [Signature Page to First Amendment to Fifth Amended and Restated Investors’ Rights Agreement]

      
        
          
 

      

    

    
      	
               

            	INVESTOR: 
	
               

            	
               

            
	
               

            	Tobin W. and Susan Juvenal
	
               

            	
               

            
	
               

            	/s/ Tobin W. and Susan Juvenal

    

  

  

  

  
    [Signature Page to First Amendment to Fifth Amended and Restated Investors’ Rights Agreement]

    
      
        
 

    

  

  
    	
             

          	INVESTOR:
	
             

          	
             

          	
             

          
	
             

          	Andrew Sassine
	
             

          	
             

          	
             

          
	
             

          	/s/ Andrew Sassine

  

  

  

  
    [Signature Page to First Amendment to Fifth Amended and Restated Investors’ Rights Agreement]

    
      
        
 

    

  

  
    	
             

          	INVESTOR:
	
             

          	
             

          	
             

          
	
             

          	
            James and Pamela Wilson Trust

            Wilson Family Partners 

          
	
             

          	
             

          	
             

          
	
             

          	By:	/s/ James Wilson
	
             

          	
            Name: James Wilson

            Title: General Partner

          

  

  

  

  
    [Signature Page to First Amendment to Fifth Amended and Restated Investors’ Rights Agreement]

    
      
        
 

    

  

  
    	
             

          	INVESTOR:
	
             

          	
             

          	
             

          
	
             

          	James and Pamela Wilson Trust
	
             

          	
             

          	
             

          
	
             

          	By:	/s/ James Wilson
	
             

          	
            Name: James Wilson

            Title: Trustee

          

  

  

  

  
    [Signature Page to First Amendment to Fifth Amended and Restated Investors’ Rights Agreement]

    
      
        
 

    

  

  
    	
             

          	INVESTOR:
	
             

          	
             

          	
             

          
	
             

          	
            Gore Range Capital Venture 1 LLC

          
	
             

          	
             

          	
             

          
	
             

          	By: Gore Range Capital, its Manager
	
             

          	
             

          	
             

          
	 	By:	/s/ Ethan Rigel
	 	
            Name: Ethan Rigel

            Title: Managing Member

          

  

  

  

  [Signature Page to First Amendment to Fifth Amended and Restated Investors’ Rights Agreement]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00297-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00297-of-00352.parquet"}]]